US20050245483A1 - Matrix for sustained, invariant and independent release of active compounds - Google Patents

Matrix for sustained, invariant and independent release of active compounds Download PDF

Info

Publication number
US20050245483A1
US20050245483A1 US10/510,673 US51067305A US2005245483A1 US 20050245483 A1 US20050245483 A1 US 20050245483A1 US 51067305 A US51067305 A US 51067305A US 2005245483 A1 US2005245483 A1 US 2005245483A1
Authority
US
United States
Prior art keywords
naloxone
pharmaceutical formulation
release
oxycodone
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/510,673
Other languages
English (en)
Inventor
Bianca Brogmann
Silke Muhlau
Christof Spitzley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28676052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050245483(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10215067A external-priority patent/DE10215067A1/de
Priority claimed from DE10215131A external-priority patent/DE10215131A1/de
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Assigned to EURO-CELTIQUE, S.A. reassignment EURO-CELTIQUE, S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SPITZLEY, CHRISTOF, BROGMAN, BRIANCA, MUHLAU, SILKE
Publication of US20050245483A1 publication Critical patent/US20050245483A1/en
Priority to US13/348,617 priority Critical patent/US8846090B2/en
Priority to US14/058,108 priority patent/US8846091B2/en
Priority to US14/489,452 priority patent/US9655855B2/en
Assigned to PURDUE PHARMA L.P. reassignment PURDUE PHARMA L.P. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EURO-CELTIQUE S.A.
Priority to US15/582,119 priority patent/US20170231978A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention concerns a storage stable pharmaceutical formulation
  • a storage stable pharmaceutical formulation comprising at least one pharmaceutically active compound in a substantially non-swellable diffusion matrix, wherein the compound is released from the matrix in a sustained and invariant, and where several compounds are present, an independent manner.
  • the matrix is formed by amounts of ethylcellulose and at least one fatty alcohol.
  • the invention also concerns a method for producing storage stable pharmaceutical formulations comprising at least one pharmaceutically active compound in a non-swellable diffusion matrix, wherein the at least one compound is released from the matrix in a sustained and invariant manner and, where several compounds are present, also an independent manner.
  • Sustained release formulations of pharmaceutical preparations take a central role in the development of improved therapies. It is the intent of all sustained release preparations to provide a longer period of pharmacological response after the administration of the drug than is ordinarily experienced after the administration of rapid release dosage forms.
  • Sustained release pharmaceutical preparations comprising relatively large amounts of the pharmaceutically active compound and that release the compounds in a controlled, regulated manner over a longer period of time (typically 2-16 hours), ensure that the frequency with which the medicine has to be taken by the patient is reduced and that higher compliance by the patients is achieved.
  • sustained release pharmaceutical preparations provide moreover for many therapeutic benefits that are not achieved with corresponding short-acting, immediate release preparations.
  • therapy may be continued e.g. overnight without the necessity to interrupt the patient's sleep. This plays a role, for instance, in the treatment of epilepsy patients, where the occurrence of nocturnal attacks may thus be prevented. In the same way, patients suffering from chronic pain are allowed undisturbed sleep.
  • sustained release formulations are the very uniform active compound concentration in the blood, leading to a long-lasting effect and reduced side effects.
  • the reduction of side effects plays a decisive role during, e.g. the use of opioids for pain therapy.
  • Opioid-induced side-effects comprise among others the danger of an addiction developing.
  • the addictive potential of an active compound is not defined by the compound itself, but rather by the way it is administered and the pharmaco-dynamic resulting therefrom (e.g. by the rate at which the brain encounters an active compound)
  • the sustained release of an opioid analgesic can reduce the addictive potential of these active compounds (Nolte, T.: STK-Zeitschrift für angewandte emptherapie, 2001, Vol. 2).
  • sustained release formulations allow for a uniformly high active compound concentration in the blood, the bio-availability of the active compound is increased.
  • factors include the active compound concentration in the respective physiological fluid (e.g. in the blood), the absorbability of the active compound across membranes (e.g. for the re-absorption in the gastro-intestinal system) and the availability of the active compound at the desired tissue site.
  • an active compound In order to be absorbed, for instance by the intestinal system, an active compound must be in solution.
  • the dissolution time of an active compound is determined as the proportion of the active compound released from a unit dosage form over a specified time based on a test method conducted under standardized conditions.
  • the physiological fluid in which the dissolution time of the active compound is determined may be, e.g. the fluid of the gastro-intestinal system.
  • the state of the art recognises may satisfactory test procedures for measuring dissolution time for pharmaceutical compositions (and correspondingly, for the release rates of the active compounds), and these test procedures are described in official compendia worldwide.
  • the surface area of the pharmaceutical composition accessible to the dissolution solvent medium is the surface area of the pharmaceutical composition accessible to the dissolution solvent medium, the pH of the dissolution solvent medium, the solubility of the active compound in the dissolution solvent medium and the saturation concentration of dissolved materials in the dissolution solvent medium.
  • sustained release pharmaceutical preparations Different approaches are known from the prior art that allow the formulation of sustained release pharmaceutical preparations. These approaches have in common that the active compound is combined with additives to shape bodies, such as tablets or dragées, with the additives forming a release or dissolution barrier for the active compound. Depending on the nature of the release barriers, different sustained release methods can be distinguished. There are, e.g. osmotic systems, systems by which retardation is achieved through coatings, or systems in which the active compounds are embedded in waxes, polymethacrylates, gel-formers or silicic acids. There are moreover the so-called matrix forms, which are of fundamental importance when formulating sustained release pharmaceutical preparations. Matrix means a shaped body comprising the active compound bound to additives which are as inert as possible.
  • matrices differ depending on whether the active compound is released by pure diffusion or by erosion of the matrix (U. Schöffling, Arzneiformenlehre, 1998, 3 rd edition, Deutscher maschiner-Verlag, Stuttgart).
  • sustained release pharmaceutical preparations having so-called controlled release of the pharmaceutically active compound, i.e. the release of the active compound is not only prolonged, but moreover can be adjusted to a predetermined release rate.
  • the release behaviour of the respective pharmaceutically active compounds may differ, the release behaviour of the active compound frequently being difficult to predict.
  • the medicament Oxygesic® which is used in pain therapy, contains e.g. oxycodone as the only analgetically active compound.
  • the medicament Kapanol® which is also used in pain therapy, comprises morphine sulfate as analgetically active compound.
  • opioid analgesics such as oxycodone may go along with the development of side effects such as breath depression and obstipation
  • co-treatment of patients with opioid antagonists that specifically counteract the opioid-induced side effects may be necessary.
  • preparations comprising an opioid analgesic simultaneous treatment with preparations comprising antagonists such as naltrexone or naloxone may be desirable in order to counteract the aforementioned side effects.
  • the opioid-containing preparation is a sustained release preparation
  • the antagonist-preparation should also provide for a sustained release as otherwise development of side effects may not effectively be repressed.
  • sustained release formulations of e.g. naloxone alone are not available on the market.
  • Sustained release formulations of combination preparations should combine in an ideal manner the positive, synergistic effects of the different active compounds with the long-lasting release and the correspondingly increased period of effectiveness.
  • Valoron® from Gödecke, which comprises tilidine as an analgetically active compound and naloxone as antagonist.
  • the change of amount of one compound may change the release profile of other compounds in an unpredictable manner in such combination preparations, resulting in significant expenditure in the production of preparations having different amounts of the active compounds, since one cannot infer from the release behaviour of one preparation the release behaviour of another one.
  • medicaments have to be formulated in a such a way that the active compounds are stable as long as possible under standard storage conditions. Medicaments also have to be formulation in such a way that the intended release profiles of the active compounds do not change during long-term storage.
  • the release profile of each single compound should be selectable as required.
  • the measures to be taken in order to achieve this should not prevent, or even hamper the release profiles of additional active compounds, e.g. in the case of combinations of different active compounds, being chosen as required. Consequently, there should be no mutual dependency of the release profiles.
  • combination preparations For a variety of therapeutic applications there is a great need for combination preparations. Particularly for pain therapy combination preparations are required that consist of opioid analgesics and corresponding antagonists, where the respective pharmaceutical preparations release both compounds in a sustained manner and also possess the aforementioned characteristics. Matrix formulations that ensure a sustained release of active compounds in general and of opioid analgesics and their antagonists in particular and that possess the aforementioned characteristics are not known from prior art.
  • German patent application DE 43 25 465 A1 concerns the treatment of side-effects during pain therapy by a preparation consisting of an opioid agonist and an antagonist.
  • the characterizing feature of this disclosure is that the antagonist must not be released in a sustained manner while the agonist should be released in a sustained manner.
  • the aforementioned pain-relief medicament Valoron® is a tilidine/naloxone-combination. According to the manufacturer's data it is a formulation from which both active compounds are released in a sustained manner.
  • the matrix used comprises a relevant part of water-swellable material hydroxypropylmethylcellulose (HPMC)) and has therefore to be considered as a swellable (and possibly partially erosive) diffusion matrix.
  • HPMC hydroxypropylmethylcellulose
  • the disadvantage of this known formulation is that tilidine and naloxone, given identical mass ratios but different absolute amounts, display different release profiles, if the release is measured for certain pH values. The release rates of the agonist and the antagonist are not independent of each other, which is probably due to the sustained release formulation used.
  • One objective of the present invention is to provide formulations for a pharmaceutical preparation that ensure that the active compounds of the preparations are released in a sustained manner, that are stable over a long storage period, and where the release of one compound does not change even when different amounts of the active compound are used.
  • a further objective of the invention is to provide formulations for pharmaceutical preparations that display the above-mentioned characteristics and that show no mutual dependency of the release profiles of the active compounds.
  • Another objective of the present invention is to provide methods for producing pharmaceutical formulations comprising at least one pharmaceutically active compound and from which the compounds are released in a sustained, reproducibly invariant and, where several compounds are present, independent manner. Such formulations should remain stable even after longer storage periods.
  • a particular objective of the present invention is to provide formulations for pharmaceutical preparations that comprise the opioid antagonist naloxone, wherein the active compound is stable over a long storage time and is released from the preparation in a sustained and reproducibly invariant manner. Formulations that achieve this, are not known from prior art.
  • An additional objective of the present invention is to provide formulations for pharmaceutical preparations for pain therapy comprising at least one opioid analgesic and at least one antagonist counteracting the opioid analgesic, wherein the formulation is stable over a long storage period and wherein the active compounds are released from the preparation independently of each other in a sustained and reproducibly invariant manner.
  • the objectives are solved by providing a pharmaceutical formulation comprising at least one pharmaceutically active compound in a substantially non-swellable diffusion matrix, wherein the matrix is formed with respect to its essential release characteristics by ethylcellulose and at least one fatty alcohol.
  • inventive matrix formulation which is stable over long storage periods permanently ensures that the active compounds are always released in predetermined percentages and that the release rates do not influence each other.
  • active compounds e.g. comprise opioid analgesics and the respective antagonists
  • abuse of the medicaments which presupposes that the agonist can be selectively extracted from the formulation, is prevented.
  • the formulation according to the invention disables selective extraction of the agonist from the preparation without the corresponding amount of the antagonist, regardless of the absolute and relative amount of agonist and antagonist chosen. Furthermore, such preparations reduce side-effects which usually occur during the application of opioids. Since the active compounds are released from the same matrix, a simplified and more efficient production process is made possible. This also applies for combination preparations comprising other compounds other than opioids analgesics or antagonists thereof.
  • the inventive formulation of a medicament ensures that given identical relative amounts, the active compounds show the same release profiles regardless of the absolute amount present.
  • Such independent release behaviour provides the physician with a wide range of usable absolute amounts of the active compounds, where the optimal compound ratio (e.g. for opioid agonist/antagonist ratios) is known. It is thus possible to comfortably adjust the dosage for each individual patient, either by increasing the dosage gradually or, if necessary, by reducing the dosage gradually. This ability to adjust the dosage for the individual patient is extremely useful from a medical point of view, as is the increased compliance.
  • inventive formulations also allow for the production of pharmaceutical preparations that release active compounds of different structures with the same release profiles.
  • the characterizing features of the present invention are the sustained, invariant, and if several active compounds are present, independent release of the active compounds from a non-swellable (at least not to an extent which is relevant for the release) diffusion matrix with the matrix being determined with respect to its essential release characteristics by ethylcellulose and at least one fatty alcohol and the active compounds remaining stable over long storage periods.
  • sustained or “controlled sustained release” or “retardation” means that pharmaceutically active substances are released from a medicament over a longer period of time than is the case with known formulations for immediate release.
  • the release takes place over a time period of two to twenty-four hours, of two to twenty hours, especially preferably over a time period of two to sixteen hours or two to twelve hours, with the specifications satisf iing legal requirements.
  • sustained release does not mean that the active compounds are released from the formulation or the medicament in a pH-dependent manner.
  • sustained release refers to the release of active compounds from a medicament over an extended period of time. It does not imply the controlled release at a defined place; it therefore does not mean that the active compounds are either released only in the stomach, or only in the intestine.
  • the release of the active compounds from the inventive formulations occurs preferably pH-independently. (Of course, a pH dependent release at a defined place could individually be achieved by, e.g. enteric coating of the medicament, although this presently seems not to be advantageous).
  • independent release means that, given the presence of at least two active compounds, a change of the absolute amount of one compound does not influence the release profiles of the other compounds so that the release profiles of the other compounds are not changed.
  • independent release behaviour is independent of the pH value, for which the release is measured, or of the production process.
  • the pH independency particularly applies to the acidic range, i.e. for pH values ⁇ 7.
  • the release profile (or release behaviour) is defined as the change of the release of the active compound from the formulation with time, with the amount of each active compound released provided in percents of the total amount of the active compound. The release profile is determined by known tests.
  • the independent release feature preferably refers to the situation where preparations of substantially equal composition are compared for the release profile. Preparations of substantially equal composition have different amounts of the active compounds but are otherwise basically the same with respect the components of the composition which essentially influence the release behaviour.
  • both preparations will provide for the same release profile for oxycodone and naloxone if the difference in the naloxone amount is replaced by a component in the formulation that typically does not influence the release behaviour.
  • the difference in the amount of naloxone may be replaced by a typical pharmaceutically inert filler such as lactose without changing the release profiles.
  • the independent release feature preferably applies to formulations that have different amounts of the active compounds but are otherwise identical or at least highly similar with respect to the components that essentially influence the release behaviour (given that formulations of the same total weight are compared).
  • “invariant release behaviour” or “invariant release profile” is defined so that the percentage of the absolute amount of each active compound released per time unit does not significantly change and remains sufficiently constant (and thus does not substantially change) if absolute amounts are changed.
  • Sufficiently constant percentages mean that the percentage released per time unit deviates from a mean value by not more than 20%, preferably by not more than 15% and especially preferably by not more than 10%.
  • the mean value is calculated from six measurements of the release profile. Of course, the amount released per time unit has to satisfy the legal and regulatory requirements.
  • the invariant release feature also preferably refers to a situation where preparations of substantially equal composition are compared. Such preparation differ with respect to the amount of the active compounds, but are of the same or at least highly similar composition with respect to the release-influencing components of the preparation. Typically, the difference in the amount of an active compound will be replaced by the amount of a pharmaceutical inert excipient which does not substantially influence the release behaviour of the preparation.
  • a pharmaceutical excipient may be lactose, which is a typical filler in pharmaceutical preparations.
  • the invariant release feature may not apply to preparations where the difference in the amount of an active compound is replaced by substances that are known to essentially influence the release behaviour of the preparation, such as ethylcellulose or fatty alcohols.
  • Example section it is set out that if one preparation comprises 20 mg oxycodone and 1 mg naloxone or 20 mg oxycodone and 10 mg naloxone, with the difference in naloxone being replaced by lactose, that the two preparations of identical weight provide for the same release profiles, so that they exhibit a sustained, invariant and independent release behaviour.
  • storage stable or “storage stability” means that upon storage under standard conditions (at least two years at room temperature and usual humidity) the amounts of the active compounds of a medicament formulation do not deviate from the initial amounts by more than the values given in the specification or the guidelines of the common Pharmacopoeias.
  • storage stability also means that a preparation produced according to the invention can be stored under standard conditions (60% relative humidity, 25° C.) as it is required for admission to the market.
  • “storage stable” or “time stable” also means that after storage under standard conditions the active compounds show release profiles as they would upon immediate use without storage.
  • the admissible fluctuations with respect to the release profile are characterized in that the amount released per time unit fluctuates by no more than 20%, preferably no more than 15% and especially preferably no more than 10%, with respect to a mean value.
  • the mean value is calculated from six measurements of the release profile.
  • the term “storage stable” refers to the active compound as well as to the other components within the inventive formulation and therefore also to the formulation as a whole.
  • the release of the active compounds from a sustained release formulation is determined by the Basket Method according to USP at pH 1.2 or pH 6.5 with HPLC.
  • Storage stability is preferably determined by the Basket Method according to USP at pH 1.2 with HPLC.
  • formulation refers to the preparation of a pharmaceutically active substance with additives (formulation aids) with the aim of enabling an optimal release, distribution and development of activity of the active compound for the respective applications.
  • a “non-swellable” or “substantially non-swellable” diffusion matrix is a matrix formulation for which the release of the active compounds is not influenced (or at least not to a relevant degree) by swelling of the matrix (particularly in the physiological fluids of the relevant target sites in the patient's body).
  • the term “substantially non-swellable” diffusion matrix also refers to a matrix whose volume will increase by approximately 300%, preferably by approximately 200%, more preferably by approximately 100%, by approximately 75% or by approximately 50%, even more preferably by approximately 30% or by approximately 20% and most preferably by approximately 15%, by approximately 10%, by approximately 5% or by approximately 1% in aqueous solutions (and particularly in the physiological fluids of the relevant target sites in the patient's body).
  • formulations for medicaments with a substantially non-swellable diffusion matrix allow for a sustained, invariant and, where several compounds are present, independent release of the active compounds, when the diffusion matrix comprises ethylcellulose as the matrix-scaffold-forming substance and is moreover determined with respect to its essential release characteristics by ethylcellulose and/or at least one fatty alcohol. Additionally, such formulations are characterized by good storage stability. Given the present knowledge, mainly formulations with such a diffusion matrix allow to release the active compounds in the aforementioned inventive manner. Formulations with a (substantially) swellable diffusion matrix or an erosive matrix are currently not considered to be suitable for that.
  • water-swellable substances and particularly water-soluble polymers may generally not be used as scaffold-forming substances for the production of matrices for formulations in accordance with the invention.
  • common matrix-forming polymers such as polyvinylpyrridone, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, poly(vinylalcohols), alginates, hydrated hydroxyalkylcellulose and hydroxypropylmethylcelluloseether are currently not considered to be suitable for the production of formulations in according with the invention.
  • Scaffold-forming substances that can form non-swellable diffusion matrices may be used for the production of formulations in accordance with the invention if they provide for a release behaviour of the active compound in accordance with the invention, i.e. for a sustained, invariant and, where several components are present, independent release, as well as for storage stability of the formulation.
  • Water-insoluble polymers, that are commonly used for the production of matrix-based sustained release pharmaceutical preparations may also not be used straightforwardly for the production of formulations in accordance with the invention.
  • Common scaffold-forming substances such as acrylic acid and methacrylic acid copolymers, methylnethacrylate copolymers, ethoxyethylmethacrylate copolymers, cyanoethylmetha-crylate, aminoalkylmethacrylate copolymers, poly(acrylic acid), poly(methacrylic acid), polymethacrylates, poly(methylmethacrylate) copolymers, polyacrylamine or alginic acid are currently not considered to be suitable for the production of formulations in accordance with the invention.
  • Matrices which are based on polymethacrylates (as e.g. Eudragit® RS30D and Eudragit® RL30D) or comprise relevant amounts of water-swellable material, particularly of hydroxyalkylcellulose such as HPMC will currently not be considered usable in accordance with the invention.
  • alkylcelluloses will generally also not be considered for the production of formulations in accordance with the invention.
  • Propylcellulose e.g. is of too lipophilic character to produce matrices with release characteristics in accordance with the invention.
  • Methylcellulose is also not suitable for the formulations in accordance with the invention.
  • the matrix that ensures the sustained release of the active compound will be selected in such a way that the release of the active compounds takes place in a sustained, invariant and, if several compounds are present, independent manner, and that the formulation is storage stable.
  • matrices comprise polymers based on ethylcellulose, with ethylcellulose being an especially preferred polymer.
  • matrices comprising polymers available on the market under the trademark Surelease®. Particularly preferred is the use of Surelease® E-7-7050.
  • retardation methods such as e.g. film coatings that ensure a sustained release
  • films coatings that ensure a sustained release
  • they are currently not considered to be suitable for production of formulations that provide for a release behaviour of the active compounds which is in accordance with the invention.
  • they are not considered to be suitable for production of formulations that ensure that the formulation is storage stable.
  • the amount of ethylcellulose (or Surelease® E-7-7050) in the matrix will vary between 1-15%, preferably between 3-12%, particularly preferably between 5-9% and even more preferably between 6-8%.
  • the percentages indicating the amount of ethylcellulose (or Surelease®) with respect to the total weight of the preparation will vary between 1-15%, preferably between 3-12%, particularly preferably between 5-9% and even more preferably between 6-8%. The percentages indicating the amount of ethylcellulose (or Surelease®) with respect to the total weight of the preparation.
  • Formulations in accordance with the preparation preferably comprise a fatty alcohol as the second component which has a sustained release effect besides ethylcellulose.
  • Fatty alcohols may comprise lauryl, myristyl, stearyl, cetylstearyl, ceryl and/or cetylalcohol.
  • stearyl and/or cetylalcohol will be used.
  • the amount of fatty alcohol in.the matrix will be between 5-30%, preferably between 10-25% and particularly preferably between 15-20%. Particularly preferred is an amount of fatty alcohol of substantially 20% (if the matrix is produced by spray granulation) or of substantially 18% (if the matrix is produced by extrusion). All percentages indicating the amount of fatty alcohol refer to the total weight of the preparation.
  • Formulations with release behaviour according to the invention comprise in particular matrices comprising ethylcellulose and at least one fatty alcohol as the components that essentially influence the release characteristics of the matrix.
  • the amount of ethylcellulose and the at least one fatty alcohol may vary significantly, so that preparations with different release profiles may be achieved. Even though the inventive preparations will usually comprise both of the aforementioned components, in some cases it may be preferred that the preparations comprise only ethylcellulose or the fatty alcohol(s) as the release determining components.
  • Formulations in accordance with the invention may comprise further components which have a sustained release effect if required. However, it has to be ensured that the release of the active compounds from the formulation and the storage stability of the formulation are in accordance with the invention and are not negatively influenced.
  • additional components with sustained release effect may comprise polyalkylene glycols and particularly preferably polyethylene glycols.
  • formulations that provide a release of the active compounds in accordance with the invention may comprise, besides the matrix forming polymers, fillers and additional substances, such as granulating aids, lubricants, dyes, flowing agents and plasticizers.
  • Lactose, glucose or saccharose, starches and their hydrolysates, microcrystalline cellulose, cellactose, sugar alcohols such as sorbitol or mannitol, poorly soluble calcium salts like calciumhydrogenphosphate, dicalcium- or tricalciumphosphate may be used as fillers.
  • Povidone may be used as granulating aid.
  • Highly-disperse silica (Aerosil®), talcum, corn starch, magnesium oxide and magnesium- and/or calcium stearate may preferably be used as flowing agents or lubricants.
  • Magnesium stearate and/or calcium stearate can preferably be used as lubricants.
  • Fatty acids like stearic acid, or fats like hydrated castor oil can also preferably be used.
  • Polyethylene glycols and fatty alcohols like cetyl and/or stearyl alcohol and/ or cetostearyl alcohol can also be used as additional substances that influence retardation.
  • compositions which are known in the art, such as surfactants, conserving agents, diluents, granulating aids, colorants, aromatic compounds, detergents, buffers and/or anti-sticking agents may also be comprised in the sustained release matrix, if the formulation still provides for a release behaviour in accordance with the invention, i.e. a sustained, invariant and, if several compounds are present, independent release.
  • Such formulations also have to provide good storage stability of the active compounds within the matrix.
  • a formulation is especially preferred that comprises ethylcellulose or Surelease® E-7-7050 as a matrix-building substance, stearyl alcohol as fatty alcohol, magnesium stearate as lubricant, lactose as filler and povidone as a granulating aid.
  • Matrices that are in accordance with the invention can be used to produce preparations that release active compounds in a sustained, independent and invariant manner and that release equal amounts of the active compounds per time unit. Specifically, this means that in the case of a oxycodone/naloxone combination containing 12 mg oxycodone und 4 mg naloxone, 25% oxycodone and 25% naloxone are released within the first 4 hours.
  • a preferred embodiment of the invention relates to preparations that release 1% to 40%, preferably 5% to 35%, more preferably between 10% and 30% and even more preferably between 15% and 25% of oxycodone and/or naloxone after 15 minutes. In other preferred embodiments of the invention, 15% to 20%, 20% to 25%, approximately 15%, approximately 20% or approximately 25% of oxycodone and/or naloxone are released after 15 minutes.
  • Another preferred embodiment of the invention relates to preparations that release between 25% to 65%, preferably between 30% to 60%, mote preferably between 35% to 55% and even more preferably between 40% to 50% of oxycodone and/or naloxone after one hour.
  • Preferred embodiments of the invention also relate to preparations that release between 40% to 45%, 45% to 50%, approximately 40%, approximately 45% or approximately 50% of oxycodone and/or naloxone after one hour.
  • Yet another preferred embodiment of the invention relates to preparations that release between 40% to 85%, preferably between 45% to 80%, more preferably between 45% to 75% and even more preferably between 45% to 55%, 50% to 60%, 55% to 65%, 65% to 75% or 75% to 85% of oxycodone and/or naloxone after 2 hours.
  • Preferred embodiments also comprise preparations that release approximately 45%, approximately 50%, approximately 55%, approximately 60%, approximately 65%, approximately 70%, approximately 75%, approximately 80% or approximately 85% of oxycodone and/or naloxone after 2 hours.
  • One preferred embodiment of the invention relates to preparations that release 60% to 100%, preferably between 75% to 95%, more preferably between 80% to 95%, and even more preferably between 80% to 90% of oxycodone and/or naloxone after 4 hours.
  • Preferred embodiments of the invention also relate to preparations that release between 80% to 85%, 85% to 90%, approximately 80%, approximately 85% or approximately 90% of oxcodone and/or naloxone after 4 hours.
  • One preferred embodiment of the invention also relates to preparations that release between 65% to 100%, preferably between 75% to 100%, more preferably between 80% to 95% and even more preferably between 80% to 85%, between 85% to 90% or between 90% to 95% of oxycodone and/or naloxone after 7 hours.
  • Preferred embodiments of the invention also relate to preparations that release approximately 80%, approximately 85%, approximately 90% or approximately 95% of oxycodone and/or naloxone after 7 hours.
  • Yet another preferred embodiment of the invention relates to preparations that release between 85% to 100%, preferably between 90% to 100%, more preferably between 95% to 100% and even more preferably approximately 95% or 100% of oxycodone and/or naloxone after 12 hours.
  • Preparations in accordance with the invention can be produced as all common application forms which, on principle, are suitable for retardation formulations and which ensure that the active compounds are released in a manner in accordance with the invention.
  • Especially suitable are tablets, multi-layer tablets and capsules.
  • Additional application forms like granules or powders can be used, with only those applications forms being admissible that provide a sufficient retardation and a release behaviour in accordance with the invention.
  • compositions may also comprise film coatings.
  • film coatings may be colored or may comprise a initial dosage of the active compounds if required. The active compounds of this initial dosage will be immediately released so that the therapeutically effective blood plasma level is reached very quickly. It has to be ensured that, by coating the preparations in accordance with the invention, the release behaviour of the active compounds is not negatively influenced.
  • the active compounds that are comprised within the formulation in accordance with the invention and which are released in a sustained, invariant and, if several compounds are present, independent manner from the inventive matrix and which are also storage stable within the matrix, are not limited to a special class of compounds.
  • Pharmaceutically active compounds according to the present invention thus comprise antipyretic, analgesic and anti-inflammatory agents such as indomethacin, aspirin, diclofenac, ibuprofren, antiulcer agents such as sulpiride, coronary vasodilaters such as nifedipine, peripheral vasodilators such as ifenprodil tartrate, antibiotics such as ampicillin, chloramphenicol or erythromycin, synthetic antimicrobial agents such as nalidixic acid, antispasmodic agents such as propantheline bromide, antitussive and antiasthmatic agents such as theophylline or aminophylline, bronchodilators such as diprophylline, diuretics such as furosemide, muscle relaxants such as chlorophenesin carbamate, cerebral metabolism improving agents such meclofenoxate hydrochloride, minor tranquilizers such as oxazolam, diazepam or clotiazepam, major
  • analgesics comprising the group of opiates and opioids such as oxycodone, morphine, dihydrocodeine, oxymorphine, buprenorphine or tramadol.
  • opioids such as oxycodone, morphine, dihydrocodeine, oxymorphine, buprenorphine or tramadol.
  • analgesic antagonists such as naltrexone or naloxone.
  • Other opioid agonists and antagonists can be found, e.g. in WO 99/32119.
  • formulations in accordance with the invention that comprise opioid analgesics (opioid agonists) and/or opioid antagonists as pharmaceutically active compounds.
  • opioid analgesics or opioid agonists comprise all compounds that belong to class NO2A of opioid analgesics according to the ATC Classification of the WHO, and that display an analgesic effect upon application in accordance with the invention.
  • an opioid agonist is selected from the. group of morphine, oxycodone, hydromorphone, propoxyphene, nicomorphine, dihydrocodeine, diamorphine, papaveretum, codeine, ethylmorphine, phenylpiperidine and derivates thereof, methadone, dextropropoxyphene, buprenorphine, pentazocine, tilidine, tramadol, hydrocodone.
  • analgesics are meperidine, oxymorphone, alphaprodine, anileridine, dextromoramide, metopone, levorphanol, phenazocine, etoheptazine, propiram, profadol, phenampromide, thiambuten, pholcodeine, codeine, dihydrocodeinon, fentanyl, 3-trans-dimethylamino-4-phenyl-4-trans-carbethoxy-A′-cyclohexen, 3-dimethylamino-0-(4-methoxyphenyl-carbamoyl)-propiophenone oxime, ( ⁇ ) ⁇ -2′-hydroxy-2, 9-dimethyl-5-phenyl-6, 7-benzomorphane, ( ⁇ )2′-hydroxy-2-(3-methyl-2-butenyl) -9-methyl-5-phenyl-6, 7-benzomorphane, pirinitramide, ( ⁇ ) ⁇ -2′-hydroxy-2,
  • Especially preferred analgesically effective opiod agonists are oxycodone, hydrocodone, hydromorphone, morphine, codeine, dihydrocodeine, methadone, oxymorphone, fentanyl and sufentanyl.
  • the opioid agonist is oxycodone.
  • antagonists comprise such compounds that counteract opioid agonists (as defined earlier). Such compounds can also be found in the ATC Classification of the WHO. According to the invention, compounds are preferred that upon application in accordance with the invention decrease the side effects , the habituation effects and the addictive potential caused by the opioid agonists.
  • Antagonists can comprise among others, naltrexone, naloxone, nalmefene, nalorphine, nalbuphine, naloxoneazinen, methylnaltrexone, ketylcyclazocine, norbinaltorphi inine, naltrindol, 6- ⁇ -naloxol and 6- ⁇ -naltrexol.
  • Especially preferred antagonists comprise naltrexone, nalmefene and naloxone. Specifically preferred as an antagonist is naloxone.
  • formulations with a combination of oxycodone as agonist and naloxone as antagonist are particularly preferred.
  • the agonist is preferably in excess compared to the antagonist.
  • the excess of the agonist is defmed based on the amount of the unit dosage of the antagonist present in the combination preparation.
  • the extent of the excess of the opioid agonist is usually given in terms of the weight ratio of agonist to antagonist.
  • preferred weight ratios of agonist to antagonist lie within a weight ratio range of 25:1 at maximum, especially preferred are the weight ratio ranges 15:1, 10:1, 5:1, 4:1, 3:1, 2:1 and 1:1.
  • agonist and antagonist are used depend on the choice of the active compounds. According to the invention, care has to be taken that agonist and antagonist are released from the pharmaceutical preparation that has been formulated for sustained release, only in an independent and invariant manner.
  • oxycodone and naloxone are used for a combination preparation, preferably between 10 and 150 mg, especially preferably between 10 and 80 mg of oxycodone (typical amounts for use) and preferably between 1 and 50 mg naloxone per unit dosage are used.
  • the preparations may comprise between 5 and 50 mg of oxycodone, between 10 and 40 mg of oxycodone, between 10 and 30 mg of oxycodone or approximately 20 mg of oxycodone.
  • Preferred embodiments of the invention may also comprise preparations with between 1 and 40 mg naloxone, 1 and 30 mg naloxone, 1 and 20 mg naloxone or between 1 and 10 mg naloxone per unit dosage.
  • the ratio between oxycodone and naloxone has to be chosen in such a way that release profiles for both active substances in accordance with the invention are guaranteed and that the agonist can display its analgesic effect while the amount of the antagonist is chosen in such a way that habituation- or addiction-promoting effects and side effects of the agonist are reduced or abolished, without (substantially) affecting the analgesic effect of the agonist.
  • development of habituation and addiction as well as obstipation and breath depression are to be considered as side effects of analgesically effective opioid agonists.
  • agonist or “antagonist” always comprises pharmaceutical acceptable and equally acting derivatives, salts and the like. If, for example, oxycodone or naloxone is mentioned, this also comprises, besides the free base, their hydrochloride, sulfate, bisulfate, tatrate, nitrate, citrate, bitratrate, phosphate, malate, maleate, hydrobromide, hydrojodide, fumarate, succinate and the like.
  • agonists and antagonists are formulated in a way that they are released from the resulting pharmaceutical preparation in a sustained, independent and invariant manner. This does not mean that the antagonist is in excess compared to the agonist. On the contrary, it is preferred that in formulations comprising an agonist/antagonist combination, that show a release profile in accordance with the invention, the agonist is in excess compared to the antagonist.
  • Preparations produced according to the invention can be applied orally, nasally, rectally and/or by inhalation for use in pain therapy.
  • parenteral application is not envisaged.
  • a formulation for oral application is especially preferred.
  • Formulations in accordance with the invention may be produced by embedding the active compound into the matrix by e.g. melting, spray-freezing, spray-drying, granulating, direct tabletting and/or extrusion.
  • Pharmaceutical preparations or preliminary stages thereof which are in accordance with the invention can be produced by build-up or break-down granulation.
  • a preferred embodiment is the production by spray granulation with subsequent drying of the granules.
  • Another preferred embodiment is the production of granules by build-up granulation in a drum or on a granulating disk. The granules may then be pressed into e.g. tablets using appropriate additional substances and procedures.
  • compositions in accordance with the invention or precursors thereof may be advantageously produced by extrusion (instead of granulation), since several working steps (such as the drying of the granulates during spray-granulation) may be omitted, so that formulations in accordance with the invention may be produced efficiently and with less cost.
  • E-7-7050 which comprises dibutylsebacat as plasticizer and additional other components may be omitted and ethylcellulose may be directly used, resulting in a cheaper and more efficient production process.
  • pharmaceutical preparations or preliminary stages thereof which are in accordance with the invention, by extrusion technology is especially advantageous.
  • pharmaceutical preparations or preliminary stages thereof are produced by melt extrusion with co- or counter-rotating extruders comprising two screws.
  • Another preferred embodiment is the production by means of extrusion, with extruders comprising one or more screws.
  • These extruders may also comprise kneading elements.
  • Extrusion is also a well-established production process in pharmaceutical technology and is well known to the person skilled in the art.
  • the person skilled in the art is well aware that during the extrusion process, various parameters, such as the feeding rate, the screw speed, the heating temperature of the different extruder zones (if available), the water content, etc. may be varied in order to produce products of the desired characteristics.
  • the Example section provides for numerous examples of preparations according to the invention that have been produced by extrusion.
  • extrusion may be performed with one or multiple screw extruders which may be counter-rotating or co-rotating screws.
  • the feeding rate of the components is dependent on the specific extruder type.
  • the temperature of the heating zones, in which the components of the inventive formulation melt may be between 40 to 120° C., preferably between 50 to 100° C., more preferably between 50 to 90° C., even more preferably between 50 to 70° C. and most preferably between 50 to 65° C., particularly if counter-rotating twin screw extruders (such as a Leistritz Micro 18 GGL) are used.
  • counter-rotating twin screw extruders such as a Leistritz Micro 18 GGL
  • the screw speed may vary between 100 to 500 revolutions per minute (rpm), preferably between 100 to 250 rpm, more preferably between 100 to 200 rpm and most preferably around 150 rpm, particularly if counter-rotating twin screw extruders (such as a Leistritz Micro 18 GGL) are used.
  • the geometry and the diameter of the nozzle may be selected as required.
  • the diameter of the nozzle of commonly used extruders typically is between 1 to 10 mm, preferably between 2 to 8 mm and most preferably between 3 to 5 mm.
  • the different extruders may differ with respect to their set up and comprise e.g. kneading elements.
  • the ratio of length versus diameter of the screw of extruders that may be used for production of inventive preparations is typically around 40:1.
  • FIGS. 1A and 1B Typical screw profiles which may be used in the production of formulations according to the invention by extrusion are shown in FIGS. 1A and 1B .
  • Extrusion procedures for the production of pharmaceutical preparations which show a sustained release are well known to the person skilled in the art.
  • a counter-rotating twin-screw extruder is used for the production of formulations in accordance with the invention.
  • This may be e.g. an extruder of the type Micro 18 GGL (Leistritz AG, Love, Germany).
  • the extruder has no kneading elements (see also FIG. 1A ).
  • the feeding rate of the components used for the production of the formulation in accordance with the invention is between 1-3 kg/h, preferably between 1-2 kg/h. Particularly preferred is a feeding rate of 1.5 kg/h.
  • the temperature of the heating zones is between 40°-120° C., 50°-100° C., preferably 50°-90° C., more preferably 50°-70° C.
  • the extruder provides for 10 heating zones. In the first heating zone the components are generally cooled around 25° C. The temperature in the other heating zones will then preferably be around 50°-65° C. and may vary for every heating zone.
  • the screw speed will be between 1-500 rpm, preferably between 1-250 rpm, more preferably between 120-200 rpm and even more preferably around 150 rpm.
  • the diameter of the nozzle will be between 1-10 mm, preferably between 2-8 mm, or between 3-5 mm. In a particularly preferred embodiment of the invention, the diameter of the nozzle is approximately 3 mm.
  • the temperatures of the heating zones have to be selected such that no temperatures develop that may destroy the pharmaceutically active compounds.
  • the feeding rate und screw speed will be selected such that the pharmaceutically active compounds are released from the preparations produced by extrusion in a sustained, independent and invariant manner and are storage stable in the matrix. If e.g. the feeding rate is increased, the screw speed may have to be increased correspondingly to ensure the same retardation.
  • the present invention allows to first produce a preparation with a desired release profile for oxycodone and naloxone or naloxone alone by e.g. varying the amount of fatty alcohols or the matrix-forming polymer ethylcellulose as well as production parameters such as temperature, screw speed (during extrusion) or pressure power during tablet production.
  • the inventive preparations according to the invention allow the person skilled in the art to change the amounts of the preparations with respect to the active compounds as outlined above. Preparations comprising different amounts of the active compounds but of otherwise substantially equal composition, however, will then provide for the features of sustained, invariant and independent release.
  • Example section therefore discloses numerous examples showing that preparations with different release profiles may be obtained by changing the amount of e.g. ethylcellulose.
  • Other examples show that once a preparation has been established with desired release profiles, the change in the amount of naloxone will not influence the release behaviour of such preparations if the difference in the amount of the active compound is replaced by pharmaceutically inert excipients such as lactose.
  • formulations in accordance with the invention by extrusion is preferred with the formulations comprising opioid analgesics and opioid antagonists as active compounds.
  • a preferred embodiment of the invention refers to a preparation that comprises the inventive matrix and naloxone as the pharmaceutically active compound. Such preparations may be advantageously used for a variety of different indications.
  • Preparations according to the invention comprising an opioid antagonist such as naloxone as the pharmaceutically active compound may e.g. be used for complete or partial treatment of opioid-induced side effects.
  • opioid-induced side effects may comprise dizziness, breath depression, opioid-abuse, development of tolerance and addiction and particularly obstipation.
  • Preparations according to the invention which comprise naloxone as a pharmaceutically active compound preferably are used for the treatment of opioid-induced obstipation.
  • opioid-induced obstipation Almost 90% of patients under opioid treatment show signs of obstipation which may be responsible for other additional ailments such as discomfort, tension and pain in the abdomen, nausea and emesis, anorexia, haemorrhoids, anal fissures, fecal incontinence, paradoxic diarrhoea, urine retention, intestinal pseudo obstruction, and decubitus of the colon which may lead to perforation (Neuenschander et. al. (2002), Palliativ Kunststofftechnik auf noir, Schweizerische Krebsliga).
  • inventive preparations comprising naloxone allow for a sustained release of the antagonist naloxone. If e.g. patients in pain are treated simultaneously with opioid analgesics, application of such preparations comprising naloxone will allow for a long term treatment of opioid-induced side effects including obstipation. Particularly, the application of naloxone as a sustained release formulation should allow for an efficient treatment of opioid-induced obstipation. At the same time it is ensured that there is no tolerance development towards opioid analgesics if applied simultaneously. Moreover, the use of naloxone does not lead to any disturbances in the water and electrolyte metabolism and does not induce colon irritation.
  • a sustained release formulation comprising naloxone as the only pharmaceutical active agent compound also has the advantage that patients that are treated with opioid analgesics may receive a dosis of naloxone which is sufficient to counteract the opioid-induced side effects without leading to a significant reduce of analgesia.
  • inventive preparations being available which comprise different amounts of naloxone, one has the possibility to specifically treat patients in need of pain treatment that receive different amounts of opioid agonists or are treated with different opioid agonists
  • Yet another preferred embodiment of the invention relates to the use of inventive preparations comprising naloxone for treatment of opioid-induced pruritus.
  • Opioid-induced puritus is one of the side effects that is experienced by the patients as extremely unpleasant.
  • preparations comprising naloxone may also be used for treatment of idiopathic syndromes such as idiopathic pruritus or pruritus due to cholestasia and/or renal dysfunction. These preparations may also be used for the treatment of chronic idiopathic obstipation or irritable bowel syndrome.
  • idiopathic syndromes such as idiopathic pruritus or pruritus due to cholestasia and/or renal dysfunction.
  • naloxone as a pharmaceutically active compound may be used for a multitude of therapeutic indications and purposes which may be either opioid-induced or not.
  • inventive preparations provide for a sustained and reproducibly invariant release behaviour, they allow for an efficient treatment of the aforementioned syndromes.
  • preparations in accordance with the invention comprising naloxone as the active compound release 30% to 60%, preferably 35% to 55%, more preferably 40% to 50% and even more preferably 40% to 45% or 45% to 50% of naloxone after 90 minutes.
  • preparations in accordance with the invention comprising naloxone release 30% to 70%, preferably 35% to 65% and more preferably between 40% to 60% of naloxone after 120 minutes.
  • preparations comprising naloxone release preferably between 35% to 40%, 40% to 45% and 45% to 50% of naloxone after 120 minutes.
  • preparations comprising naloxone release approximately 35%, approximately 40%, approximately 45%, approximately 50% or approximately 55% of naloxone after 120 minutes.
  • preparations in accordance with the invention comprising naloxone release 55% -90%, preferably 60% to 80%, more preferably 65% to 75% and even more preferably 65% to 70% or 70% to 75% of naloxone after 420 minutes.
  • preparations comprising naloxone release approximately 65%, approximately 70% or approximately 75% of naloxone after 420 minutes.
  • preparations in accordance with the invention comprising naloxone release 60% to 90%, preferably 65% to 85%, more preferably 70% to 80% and even more preferably 75% to 80% of naloxone after 600 minutes.
  • preparations comprising naloxone release approximately 75%, approximately 80% or approximately 85% of naloxone after 600 minutes.
  • Examples that display highly advantageous embodiments of the invention are set out below. Examples are also given showing that formulations which are in accordance with the invention differ mainly in their structure from formulations with a sustained release which has been produced by using commonly used scaffold-forming polymers. Only the formulations produced in accordance with the invention provide for a sustained, invariant and, if several compounds are present, independent release of the active compounds with the formulation being storage stable. The examples are not to be interpreted as limiting the possible embodiments of the invention.
  • Surelease® E-7-7050 polymer mixture used had the following composition.
  • Surelease ® Ethylcellulose 20 cps Dibutylsebacate Ammoniumhydroxide Oleic acid Siliciumdioxide Water
  • oxycodone HCl, naloxone HCl, Povidone 30 and Lactose Flow Lac 100 were mixed in a tumbling mixer (Bohle) and subsequently spray-granulated with Surelease® E-7-7050 in a fluidized bath granulating device (GPCG3). The material was sieved over a Comill 1.4 mm sieve. An additional granulation step was carried out with melted fatty alcohol in a high-shear mixer (Collette). All tablet cores produced by this approach had a weight of 123 mg, based on dry substance.
  • the listed amounts of oxycodone HCl, naloxone HCl, ethylcellulose 45 cpi, Povidone 30, stearyl alcohol and Lactose Flow Lac 100 were mixed in a tumbling mixer (Bohle). This mixture was subsequently extruded with a counter-rotating twin screw extruder of the type Micro 18 GGL (Leistritz AG, Love, Germany).
  • the temperature of heating zone 1 was 25° C., of heating zone 2, 50° C., of heating zones 3 to 5, 60° C., of heating zones 6 to 8, 55° C., of heating zone 9, 60° C. and of heating zone 10, 65° C.
  • the screw rotating speed was 150 revolutions per minute (rpm)
  • the resulting melt temperature was 87° C
  • the feed rate was 1.5 kg/h
  • the diameter of the nozzle opening was 3 mm.
  • the extruded material was sieved with a Frewitt 0.68 ⁇ 1.00 mm sieve.
  • the grinded extrudate was then mixed with talcum and magnesium stearate that had been added over a 1 mm hand sieve and was subsequently pressed into tablets.
  • the extruder has a screw geometry, as shown in FIG. 1A .
  • extruded preparations comprise less components.
  • the release of the active compounds was measured over a time period of 12 hours, applying the Basket Method according to USP at pH 1.2 using HPLC. Tablets Ox/Nal-0, Ox/Nal-5 and Ox/Nal-10 were tested.
  • the release values refer to oxycodone or naloxone (line 2) and are given as percentages.
  • the mean value for the release of naloxone at e. g. 420 min is 92,7%.
  • the maximal deviation at 420 min is 1%.
  • Oxy and Nal stand for oxycodone and naloxone and indicate the active compound which has been measured.
  • the release of active compounds from the tablets was measured over a time period of 12 hours at pH 1.2 or for 1 hour at 1.2 and subsequently for 11 hours at pH 6.5. Release rates were determined by the basket method according to USP using HPLC.
  • the release rates refer to oxycodone and naloxone (line 2) and are given as percentages. Oxy and Nal stand for oxycodone and naloxone and indicate the active compound measured.
  • naloxone is released from spray-granulated tablets (Ox/Nal-10-tablets, see Example 3) at 420 minutes, while 93.9% is released from extruded tablets (Oxy/Nal-Extr.-1.2-O, Example 4) at 420 minutes.
  • the release of naloxone from extruded tablets thus deviates by 1.3% from the mean value of the release of naloxone from spray-granulated tablets (92.7% at 420 minutes).
  • Valoron® tablets with 50 mg tilidine and 4 mg naloxone (Ti/Nal-50/4) or 100 mg tilidine and 8 mg naloxone (Ti/Nal-100/8) or 150 mg tilidine and 12 mg naloxone (Ti/Nal-150/12) were tested by the Basket Method according to USP for 1 h at pH 1.2 and then for additional 6h at pH 6.5 using HPLC.
  • the release values refer to tilidine or naloxone (line 2) and are given as percentages.
  • the mean value for the release of naloxone at e. g. 420 min is 78,87%.
  • the maximal deviation at 420 min is 20,4%.
  • Til und Nal stand for tilidine and naloxone and indicate the active compound tested.
  • FIGS. 5A and 5B show different magnifications of scanning electron microscopy pictures of a Ox/Nal-10-tablet with a formulation according to the invention which was produced by spray granulation.
  • FIGS. 5A and 5B show different magnifications of scanning electron microscopy pictures of a Ox/Nal-10-tablet with a formulation according to the invention which was produced by spray granulation.
  • FIGS. 6A and 6B show different magnifications of scanning electron microscopy pictures of a Oxy/Nal-Extr-tablets with a formulation according to the invention, which was produced by extrusion.
  • FIGS. 7A and 7B show scanning electron microscopy pictures of the Valoron® N-tablet.
  • tablets with a formulation according to the invention have a surface which is substantially finer and more homogeneously structured and which shows fewer cracks than the Valoron® tablet, regardless of whether the tablets have been produced by spray granulation or extrusion.
  • the structural difference is possibly the reason for the different release behaviours of the different preparations.
  • EUDRAGIT® 30 D can be purchased from Röhm GmbH, Darmstadt. Surelease® can be purchased from Colorcon Ltd., Idstein.
  • naloxone HCl, Povidone 30 and Lactose Flow Lac 100 were mixed in a tumbling mixer (Bohle) and subsequently spray-granulated with EUDRAGIT® RS 30 D or Surelease® in a fluidized bath granulating device (GPCG3).
  • An additional granulation step was carried out with melted fat alcohol in a high-shear mixer (Collette). All tablet cores produced by this approach had a weight of 125 mg, referred to the dry substance.
  • naloxone HCl, ethylcellulose 45 cpi, Kollidone 30, stearyl alcohol and Lactose Flow Lac 100 were mixed in a tumbling mixer (Bohle). This mixture was subsequently extruded with a counter-rotating twin screw extruder of the type Micro 18 GGL (Leistritz AG, Love, Germany). The temperature of heating zone 1 was 25° C., of heating zone 2, 50° C., of heating zones 3 to 10, 55° C. The screw rotating speed was 140 rpm, the resulting melt temperature was 65° C., the feed rate was 1.25 kg/h and the diameter of the nozzle opening was 3 mm.
  • the extruded material was sieved with a Frewitt 0.68 ⁇ 1.00 mm sieve.
  • the grinded extrudate was then mixed with talcum and magnesium stearate that had been added over a 1 mm hand sieve and was subsequently pressed into tablets.
  • the extruder has a screw geometry, as shown in FIG. 1 .
  • extruded preparations comprise less components.
  • the release of the active compound was measured over a time period of 16 hours, applying the Basket Method according to USP at pH 1.2 using HPLC. Two tablets (designated A and B) of Nal-5-Eud, Nal-5-Sure and Nal-10-Sure were tested.
  • the release values refer to naloxone and are given as percentages.
  • the mean value for the release of naloxone in the case of e.g. Nal-Sure tablets at 90 min is 46.3%.
  • the maximal deviation at 90 mnin is 2.2%.
  • the mean value at this time point for Nal-Eud tablets is 33.3% and the deviation is 21.5%.
  • the release of the active compound was measured for different tablets over a time period of 12 hours, applying the Basket Method according to USP at pH 1.2 using HPLC.
  • the release values refer to naloxone and are given as percentages.
  • the mean value for the release of naloxone in the case of Nal-Extr tablets at 120 min is 40.9%.
  • the maximal deviation at 120 min is 2.4%.
  • FIGS. 10A and 10B show different magnifications of scanning electron microscopy pictures of a Nal-5-Eud tablet.
  • FIGS. 11A and 11B show different magnifications of scanning electron microscopy pictures of a Nal-Extr tablets with a formulation in accordance with the invention.
  • the formulation in accordance with the invention has a surface which is substantially finer and more homogeneously structured. Particularly, in FIGS. 10A and 10B naloxone blooms can be seen, but not in FIGS. 11A and 11B . This structural difference is possibly the reason for the different release behaviour of the different preparations.
  • Example 7 For electron microscopy, granulates as they were used for production of Nal-Sure tablets according to Example 7 witt 10 mg naloxone (Nal-10-Sure) and Nal-Extr tablets according to Example 8 were used.
  • FIGS. 12A and 12B show different magnifications of scanning electron microscopy pictures of Nal-10-Sure granulates.
  • FIGS. 13A and 13B show different magnifications of scanning electron microscopy pictures of a Nal-Extr granulates with a formulation in accordance with the invention.
  • Example 1 Multiple tablets comprising either EUDRAGIT® RS 30 D or Surelease® and 5 mg naloxone were produced as described in Example 1. The tablets were stored at 25° C. and 60% relative humidity. At different time points, the release behaviour was tested as described in Example 4.
  • the release profiles of naloxone tablets having been formulated with EUDRAGIT® RS 30 D differ already after a short time of storage.
  • the release profile of tablets which have been formulated with Surelease® are almost invariant, even after 15 months of storage.
  • Tablet production was performed with a common tabletting device with the following parameters: OxN20/1-Extr-A: rpm: 40 rpm Pressure power: 9 kN OxN20/1-Extr-B: rpm: 42 rpm Pressure power: 8.9 kN OxN20/1-Extr-C: rpm: 36 rpm Pressure power: 9 kN OxN20/10-Extr-A: rpm: 36 rpm Pressure power: 7.5 kN
  • the release of the active compounds was measured over a time period of 12 hours, applying the Basket Method according to USP at pH 1.2 using HPLC. Tablets OxN20/1-Extr-A, OxN20/1-Extr-B, OxN20/1-Extr-C and OxN20/10-Extr-A were tested.
  • the release values refer to oxycodone or naloxone (line 2) and are given as percentages.
  • the mean value for the release of naloxone at e. g. 420 min is 92.3%.
  • the maximal deviation at 420 min is 7.4%.
  • Oxy and Nal stand for oxycodone and naloxone and indicate the active compound which has been measured.
  • Extrusion was performed as described above (Example 2) with the following parameters: OxN20/1-Extr-D: temperature: 55-63° C. rpm (screw): 150 rpm feeding rate: 1.5 kg/h OxN20/1-Extr-E: temperature: 55-63° C. rpm (screw): 150 rpm feeding rate: 1.5 kg/h OxN20/10-Extr-B: temperature: 55-63° C. rpm (screw): 160 rpm feeding rate: 1.75 kg/h OxN20/10-Extr-C: temperature: 55-63° C.
  • Tablet production was performed with a common tabletting device with the following parameters: OxN20/1-Extr-D: rpm: 39 rpm Pressure power: 11 kN OxN20/1-Extr-E: rpm: 39 rpm Pressure power: 10.5 kN OxN20/10-Extr-B: rpm: 36 rpm Pressure power: 9.5 kN OxN20/10-Extr-C: rpm: 36 rpm Pressure power: 7.8 kN OxN20/10-Extr-D: rpm: 39 rpm Pressure power: 9 kN OxN20/10-Extr-E: rpm: 39 rpm Pressure power: 7.5 kN
  • the release of the active compounds was measured over a time period of 12 hours, applying the Basket Method according to USP at pH 1.2 using HPLC. Tablets OxN20/1-Extr-D, OxN20/1-Extr-E, OxN20/10-Extr-B, OxN20/10-Extr-C, OxN20/10-Extr-D and OxN20/10-Extr-E were tested.
  • the release values refer to oxycodone or naloxone (line 2) and are given as percentages. Oxy and Nal stand for oxycodone and naloxone and indicate the active compound which has been measured.
  • preparations with particular release profiles may be produced if ethylcellulose and fatty alcohols are used as the matrix-components that essentially influence the release characteristics of the preparations. Once a preparation with desired release characteristics has been obtained the amount of the active compounds may be changed. The preparations will still provide for a sustained, independent and invariant release behaviour (see example 14).
  • N10-Extr-1 temperature: 55-63° C. rpm (screw): 120 rpm feeding rate: 1.5 kg/h
  • N10-Extr-2 temperature: 55-63° C. rpm (screw): 140 rpm feeding rate: 1.5 kg/h
  • N10-Extr-3 temperature: 55-63° C. rpm (screw): 160 rpm feeding rate: 1.75 kg/h
  • N10-Extr-4 temperature: 55° C. rpm (screw): 120 rpm feeding rate: 1.75 kg/h
  • N10-Extr-5 temperature: 55-55° C. rpm (screw): 140 rpm feeding rate: 1.5 kg/h
  • N10-Extr-6 temperature: 55° C. rpm (screw): 160 rpm feeding rate: 1.5 kg/h
  • the release values refer to naloxone and are given as percentages.
  • the mean value for the release of naloxone at e. g. 420 min is 67.8%.
  • the maximal deviation at 420 min is 2.5%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US10/510,673 2002-04-05 2003-04-04 Matrix for sustained, invariant and independent release of active compounds Abandoned US20050245483A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/348,617 US8846090B2 (en) 2002-04-05 2012-01-11 Matrix for sustained, invariant and independent release of active compounds
US14/058,108 US8846091B2 (en) 2002-04-05 2013-10-18 Matrix for sustained, invariant and independent release of active compounds
US14/489,452 US9655855B2 (en) 2002-04-05 2014-09-17 Matrix for sustained, invariant and independent release of active compounds
US15/582,119 US20170231978A1 (en) 2002-04-05 2017-04-28 Matrix for sustained, invariant and independent release of active compounds

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10215131.8 2002-04-05
DE10215067A DE10215067A1 (de) 2002-04-05 2002-04-05 Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst
DE10215131A DE10215131A1 (de) 2002-04-05 2002-04-05 Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
DE10215067.2 2002-04-05
PCT/EP2003/003541 WO2003084504A2 (en) 2002-04-05 2003-04-04 Matrix for sustained, invariant and independent release of active compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/003541 A-371-Of-International WO2003084504A2 (en) 2002-04-05 2003-04-04 Matrix for sustained, invariant and independent release of active compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/348,617 Continuation US8846090B2 (en) 2002-04-05 2012-01-11 Matrix for sustained, invariant and independent release of active compounds

Publications (1)

Publication Number Publication Date
US20050245483A1 true US20050245483A1 (en) 2005-11-03

Family

ID=28676052

Family Applications (11)

Application Number Title Priority Date Filing Date
US10/510,673 Abandoned US20050245483A1 (en) 2002-04-05 2003-04-04 Matrix for sustained, invariant and independent release of active compounds
US10/510,674 Abandoned US20050245556A1 (en) 2002-04-05 2003-04-04 Pharmaceutical preparation containing oxycodone and naloxone
US13/251,172 Abandoned US20120108621A1 (en) 2002-04-05 2011-09-30 Pharmaceutical preparation containing oxycodone and naloxone
US13/348,617 Expired - Lifetime US8846090B2 (en) 2002-04-05 2012-01-11 Matrix for sustained, invariant and independent release of active compounds
US14/058,068 Abandoned US20140045877A1 (en) 2002-04-05 2013-10-18 Pharmaceutical preparation containing oxycodone and naloxone
US14/058,108 Expired - Lifetime US8846091B2 (en) 2002-04-05 2013-10-18 Matrix for sustained, invariant and independent release of active compounds
US14/305,785 Expired - Fee Related US9555000B2 (en) 2002-04-05 2014-06-16 Pharmaceutical preparation containing oxycodone and naloxone
US14/489,452 Expired - Fee Related US9655855B2 (en) 2002-04-05 2014-09-17 Matrix for sustained, invariant and independent release of active compounds
US15/399,487 Expired - Lifetime US9907793B2 (en) 2002-04-05 2017-01-05 Pharmaceutical preparation containing oxycodone and naloxone
US15/582,119 Abandoned US20170231978A1 (en) 2002-04-05 2017-04-28 Matrix for sustained, invariant and independent release of active compounds
US15/881,459 Expired - Lifetime US10420762B2 (en) 2002-04-05 2018-01-26 Pharmaceutical preparation containing oxycodone and naloxone

Family Applications After (10)

Application Number Title Priority Date Filing Date
US10/510,674 Abandoned US20050245556A1 (en) 2002-04-05 2003-04-04 Pharmaceutical preparation containing oxycodone and naloxone
US13/251,172 Abandoned US20120108621A1 (en) 2002-04-05 2011-09-30 Pharmaceutical preparation containing oxycodone and naloxone
US13/348,617 Expired - Lifetime US8846090B2 (en) 2002-04-05 2012-01-11 Matrix for sustained, invariant and independent release of active compounds
US14/058,068 Abandoned US20140045877A1 (en) 2002-04-05 2013-10-18 Pharmaceutical preparation containing oxycodone and naloxone
US14/058,108 Expired - Lifetime US8846091B2 (en) 2002-04-05 2013-10-18 Matrix for sustained, invariant and independent release of active compounds
US14/305,785 Expired - Fee Related US9555000B2 (en) 2002-04-05 2014-06-16 Pharmaceutical preparation containing oxycodone and naloxone
US14/489,452 Expired - Fee Related US9655855B2 (en) 2002-04-05 2014-09-17 Matrix for sustained, invariant and independent release of active compounds
US15/399,487 Expired - Lifetime US9907793B2 (en) 2002-04-05 2017-01-05 Pharmaceutical preparation containing oxycodone and naloxone
US15/582,119 Abandoned US20170231978A1 (en) 2002-04-05 2017-04-28 Matrix for sustained, invariant and independent release of active compounds
US15/881,459 Expired - Lifetime US10420762B2 (en) 2002-04-05 2018-01-26 Pharmaceutical preparation containing oxycodone and naloxone

Country Status (33)

Country Link
US (11) US20050245483A1 (enrdf_load_stackoverflow)
EP (17) EP2311438A1 (enrdf_load_stackoverflow)
JP (5) JP4620355B2 (enrdf_load_stackoverflow)
KR (3) KR100717591B1 (enrdf_load_stackoverflow)
CN (4) CN100411611C (enrdf_load_stackoverflow)
AP (2) AP2043A (enrdf_load_stackoverflow)
AR (3) AR039378A1 (enrdf_load_stackoverflow)
AT (1) ATE418967T2 (enrdf_load_stackoverflow)
AU (2) AU2003224040B2 (enrdf_load_stackoverflow)
BR (2) BRPI0309544B8 (enrdf_load_stackoverflow)
CA (3) CA2478523A1 (enrdf_load_stackoverflow)
CO (2) CO5611100A2 (enrdf_load_stackoverflow)
CY (5) CY1108914T1 (enrdf_load_stackoverflow)
DE (6) DE60325567D1 (enrdf_load_stackoverflow)
DK (6) DK1492505T3 (enrdf_load_stackoverflow)
ES (7) ES2733051T1 (enrdf_load_stackoverflow)
FI (1) FI7846U1 (enrdf_load_stackoverflow)
GE (3) GEP20074022B (enrdf_load_stackoverflow)
HK (2) HK1246176A1 (enrdf_load_stackoverflow)
HU (4) HUE027004T2 (enrdf_load_stackoverflow)
IL (5) IL163990A0 (enrdf_load_stackoverflow)
LT (3) LT2425825T (enrdf_load_stackoverflow)
MA (2) MA27116A1 (enrdf_load_stackoverflow)
MX (2) MXPA04009714A (enrdf_load_stackoverflow)
NZ (1) NZ535286A (enrdf_load_stackoverflow)
PH (1) PH12018000176A1 (enrdf_load_stackoverflow)
PT (5) PT2425821T (enrdf_load_stackoverflow)
RU (3) RU2295344C2 (enrdf_load_stackoverflow)
SI (5) SI1492506T1 (enrdf_load_stackoverflow)
TN (1) TNSN04192A1 (enrdf_load_stackoverflow)
TW (3) TWI334779B (enrdf_load_stackoverflow)
WO (2) WO2003084504A2 (enrdf_load_stackoverflow)
ZA (2) ZA200407267B (enrdf_load_stackoverflow)

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245556A1 (en) * 2002-04-05 2005-11-03 Bianca Brogmann Pharmaceutical preparation containing oxycodone and naloxone
US20060194826A1 (en) * 2003-09-25 2006-08-31 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
US20070185147A1 (en) * 2004-06-08 2007-08-09 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
US20070259045A1 (en) * 2005-01-28 2007-11-08 Euro-Celtique S.A. Alcohol Resistant Dosage Forms
US20080145429A1 (en) * 2005-02-28 2008-06-19 Petra Leyendecker Dosage Form Containing Oxycodone and Naloxone
US20090142398A1 (en) * 2007-11-21 2009-06-04 Pharmascience Inc. Novel pharmaceutical compositions comprising a disintegration matrix
US20090169626A1 (en) * 2006-01-27 2009-07-02 Euro-Celtique S.A. Tamper resistant dosage forms
US7658939B2 (en) 2000-02-08 2010-02-09 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US20100047340A1 (en) * 2008-08-20 2010-02-25 Board Of Regents, The University Of Texas System Hot-melt extrusion of modified release multi-particulates
US20100056554A1 (en) * 2006-08-29 2010-03-04 Jo Woodward Use of opioid formulations in needle-less drug delivery devices
US20110002985A1 (en) * 2007-08-13 2011-01-06 Abuse Deterrent Pharmaceutical, Llc Abuse resistant drugs, method of use and method of making
US7914818B2 (en) 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US7943173B2 (en) 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
WO2010140007A3 (en) * 2009-06-05 2011-11-17 Euro-Celtique S.A. Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug
US8268349B2 (en) 2003-08-28 2012-09-18 Abbott Laboratories Solid pharmaceutical dosage form
US8362029B2 (en) 2008-12-31 2013-01-29 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8518925B2 (en) 2004-06-08 2013-08-27 Euro-Celtique S.A. Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US8673355B2 (en) 1997-12-22 2014-03-18 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8822487B2 (en) 1997-12-22 2014-09-02 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
US8951555B1 (en) 2000-10-30 2015-02-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US8975273B2 (en) 1999-10-29 2015-03-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9023390B2 (en) 2009-09-17 2015-05-05 Upsher-Smith Laboratories, Inc. Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
US9101625B2 (en) 2006-08-30 2015-08-11 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9149436B2 (en) 2003-04-21 2015-10-06 Purdue Pharma L.P. Pharmaceutical product comprising a sequestered agent
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9642801B2 (en) 2008-10-30 2017-05-09 Gruenenthal Gmbh And potent tapentadol dosage forms
US9700508B2 (en) 2010-05-10 2017-07-11 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
US9707224B2 (en) 2013-10-31 2017-07-18 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
US9974751B2 (en) 2006-09-15 2018-05-22 Cima Labs Inc. Abuse resistant drug formulation
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10420726B2 (en) 2013-03-15 2019-09-24 Inspirion Delivery Sciences, Llc Abuse deterrent compositions and methods of use
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11992468B2 (en) 2019-05-07 2024-05-28 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
GB0501638D0 (en) * 2005-01-28 2005-03-02 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
UA95993C2 (ru) * 2004-08-13 2011-09-26 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
ES2377214T3 (es) 2004-08-13 2012-03-23 Boehringer Ingelheim International Gmbh Formulación en comprimidos de liberación extendida que contiene pramipexol o una sal farmacéuticamente aceptable del mismo
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1810678A1 (de) 2006-01-19 2007-07-25 Holger Lars Hermann Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
AU2011202866B2 (en) * 2006-01-27 2012-06-14 Mundipharma Pty Limited Tamper resistant dosage forms
US20080171762A1 (en) * 2007-01-16 2008-07-17 Ockert David M Treatment of pain with naloxone
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
RU2007137044A (ru) * 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) Лекарственное средство, обладающее гемопоэзстимулирующим и гепатопротекторным действием
MX2010008138A (es) 2008-01-25 2010-08-10 Gruenenthal Gmbh Forma de dosis farmaceutica.
RU2363468C1 (ru) * 2008-04-03 2009-08-10 Сергей Константинович Судаков Применение производных налоксона и налтрексона для приготовления обезболивающих лекарственных средств
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
BRPI0910780A2 (pt) * 2008-07-07 2016-08-09 Euro Celtique Sa uso de antagonistas de opióides para o tratamento da retenção urinária
EP2456424B1 (en) 2009-07-22 2013-08-28 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
US9125867B2 (en) * 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
JP2013537531A (ja) 2010-08-04 2013-10-03 トーマス・ジュリアス・ボロディ 糞便細菌叢移植のための組成物ならびにそれを作製および使用する方法ならびにそれを送達するためのデバイス
BR112013003150B1 (pt) * 2010-08-13 2022-01-18 Euro-Celtique S.A. Uso de hidroxipropil celulose para a fabricação de formulações estáveis em armazenagem
RU2607499C2 (ru) 2010-09-02 2017-01-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
HRP20151420T4 (hr) * 2010-09-30 2019-04-05 Astrazeneca Ab Kristalni konjugat naloksol-peg
MX355760B (es) 2010-12-13 2018-04-27 Salix Pharmaceuticals Inc Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas.
JP2014507481A (ja) 2011-03-09 2014-03-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 結腸微生物相移植のための組成物及び方法
AT511581A1 (de) 2011-05-26 2012-12-15 G L Pharma Gmbh Orale retardierende formulierung
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
CA2839126A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
BR112014004789A2 (pt) * 2011-08-29 2017-03-21 Dsm Ip Assets Bv extrusor de laboratório e método para produzir produtos farmacêuticos
KR20140075704A (ko) 2011-10-06 2014-06-19 그뤼넨탈 게엠베하 오피오이드 작용제 및 오피오이드 길항제를 포함하는 변형억제 경구용 약제학적 용량형
AU2012338872B2 (en) 2011-11-17 2017-06-22 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer
AU2013225106B2 (en) 2012-02-28 2017-11-02 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AR092820A1 (es) 2012-04-17 2015-05-06 Purdue Pharma Lp Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
AU2013248351B2 (en) 2012-04-18 2018-04-26 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
CN110170050A (zh) 2012-06-04 2019-08-27 高拉夫·阿格拉沃尔 用于治疗克罗恩氏病和相关病况以及感染的组合物和方法
JP6454640B2 (ja) 2012-07-27 2019-01-16 レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． 結腸排出促進における使用のための製剤および製剤製造方法
WO2014093871A1 (en) * 2012-12-14 2014-06-19 Trevi Therapeutics, Inc. Methods for treating pruritus
EP2991649B1 (en) 2013-04-30 2020-06-03 Thomas Julius Borody Compositions for treating obsessive-compulsive disorder
ES2718211T3 (es) 2013-05-24 2019-06-28 Rhodes Tech Compuestos cetales opioides y usos de los mismos
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
WO2015086528A1 (de) * 2013-12-11 2015-06-18 Develco Pharma Schweiz Ag Naloxon-monopräparat und mehrschichttablette
US10105360B2 (en) 2013-12-11 2018-10-23 Develco Pharma Schweiz Ag Method and composition for the treatment of opioid induced constipation
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
SG10202003562WA (en) 2014-03-14 2020-05-28 Opiant Pharmaceuticals Inc Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
US9901603B2 (en) 2015-05-14 2018-02-27 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
HUE058209T2 (hu) 2015-05-22 2022-07-28 Univ Arizona State Módszerek az autizmus spektrum zavar és azzal összefüggõ tünetek kezelésére
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3352773B1 (en) 2015-09-24 2024-12-18 San Diego State University (SDSU) Foundation DBA San Diego State University Research Foundation Antibacterial and protective bacteriophage formulations and methods for making and using them
JP7023859B2 (ja) 2016-03-31 2022-02-22 スペックジーエックス エルエルシー 徐放性乱用防止剤形
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
EP3290027A1 (en) * 2016-09-02 2018-03-07 Develco Pharma Schweiz AG Method and composition for the treatment of opioid induced constipation
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CN110831606A (zh) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
BR112019027889A2 (pt) 2017-06-30 2020-07-07 Purdue Pharma L.P. método de tratamento e formas de dosagem do mesmo
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 健康な腸バリアを維持及び回復するための組成物及び方法
WO2019152002A1 (en) * 2018-01-31 2019-08-08 Dharma Laboratories LLC Non-extractable oral solid dosage forms
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
WO2019165298A1 (en) 2018-02-23 2019-08-29 Rhodes Technologies Novel opioid compounds and uses thereof
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CA3106995A1 (en) 2018-07-23 2020-01-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness, or dyspnea with nalbuphine compositions
EP3856212A1 (en) 2018-09-27 2021-08-04 Finch Therapeutics Holdings LLC Compositions and methods for treating epilepsy and related disorders
EP3999085B1 (en) 2019-07-19 2025-03-12 Finch Therapeutics Holdings LLC Methods and products for treatment of gastrointestinal disorders
US20220378855A1 (en) 2019-12-20 2022-12-01 Persephone Biosciences, Inc. Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same
MX2022008554A (es) 2020-01-10 2022-08-10 Trevi Therapeutics Inc Metodos de administracion de nalbufina.

Citations (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133132A (en) * 1960-11-29 1964-05-12 Univ California High flow porous membranes for separating water from saline solutions
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3546876A (en) * 1967-11-02 1970-12-15 Philips Corp Hot-gas engine
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3950508A (en) * 1972-05-10 1976-04-13 Laboratoires Servier Process for obtaining pharmaceutical sustained releases
US3966040A (en) * 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4088864A (en) * 1974-11-18 1978-05-09 Alza Corporation Process for forming outlet passageways in pills using a laser
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4160020A (en) * 1975-11-24 1979-07-03 Alza Corporation Therapeutic device for osmotically dosing at controlled rate
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4582835A (en) * 1983-12-06 1986-04-15 Reckitt & Colman Products Limited Analgesic compositions
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4957681A (en) * 1988-04-15 1990-09-18 Basf Aktiengesellschaft Preparation of pharmaceutical mixtures
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5591452A (en) * 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5958452A (en) * 1994-11-04 1999-09-28 Euro-Celtique, S.A. Extruded orally administrable opioid formulations
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6103261A (en) * 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
US6114326A (en) * 1998-03-27 2000-09-05 Pharmacia & Upjohn Company Use of cabergoline in the treatment of restless legs syndrome
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6258042B1 (en) * 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
US6277384B1 (en) * 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6306438B1 (en) * 1997-07-02 2001-10-23 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
US20010053777A1 (en) * 1999-08-19 2001-12-20 Brecht Hans Michael Drug treatment for restless leg syndrome
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US20020010127A1 (en) * 2000-02-08 2002-01-24 Benjamin Oshlack Controlled-release compositions containing opioid agonist and antagonist
US20020031552A1 (en) * 2000-06-30 2002-03-14 Mcteigue Daniel Teste masked pharmaceutical particles
US6419959B1 (en) * 1996-12-11 2002-07-16 Klinge Pharma Gmbh Galenic composition containing opioid antagonists
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030069263A1 (en) * 2001-07-18 2003-04-10 Breder Christopher D. Pharmaceutical combinations of oxycodone and naloxone
US20030092759A1 (en) * 2001-09-24 2003-05-15 Abuzzahab Faruk S. Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US6596900B2 (en) * 2001-04-19 2003-07-22 Pfizer Inc Fused bicyclic or tricyclic amino acids
US6602868B2 (en) * 2000-10-31 2003-08-05 Pharmacia & Upjohn Company Treatments for restless legs syndrome
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US6696088B2 (en) * 2000-02-08 2004-02-24 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
US20040052731A1 (en) * 2002-07-05 2004-03-18 Collegium Pharmaceuticals, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20050272776A1 (en) * 2004-06-04 2005-12-08 Adolor Corporation Compositions containing opioid antagonist
US20070185146A1 (en) * 2004-06-08 2007-08-09 Euro-Celtique S.A. Opioids for the treatment of the chronic obstructive pulmonary disease (copd)
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20080145429A1 (en) * 2005-02-28 2008-06-19 Petra Leyendecker Dosage Form Containing Oxycodone and Naloxone

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2770569A (en) 1952-08-01 1956-11-13 Hoffmann La Roche Analgesic compositions
US3173877A (en) 1957-09-09 1965-03-16 Wyandotte Chemicals Corp Detergent compositions comprising inorganic esters of epoxyhydrocarbon polymers
US3493657A (en) 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3879555A (en) 1970-11-16 1975-04-22 Bristol Myers Co Method of treating drug addicts
US3676557A (en) 1971-03-02 1972-07-11 Endo Lab Long-acting narcotic antagonist formulations
GB1390772A (en) * 1971-05-07 1975-04-16 Endo Lab Oral narcotic composition
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US3966940A (en) 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
LU77339A1 (enrdf_load_stackoverflow) 1977-05-16 1979-01-19
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4237140A (en) 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4401672A (en) 1981-10-13 1983-08-30 Regents Of The University Of Minnesota Non-addictive narcotic antitussive preparation
US4608376A (en) 1981-10-16 1986-08-26 Carolyn McGinnis Opiate agonists and antagonists
EP0103636B1 (en) * 1982-03-16 1990-09-12 Rockefeller University Use of opium antagonists for the manufacture of medicaments for controlling gastrointestinal dysmotility
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4443428A (en) 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4803208A (en) 1982-09-30 1989-02-07 Sloan-Kettering Institute For Cancer Research Opiate agonists and antagonists
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
DE3434946A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Diarylacetylene, ihre herstellung und verwendung
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
ZA861211B (en) 1985-02-25 1987-10-28 Lilly Co Eli Analgesic composition
JPS61280423A (ja) 1985-06-05 1986-12-11 Kiyuukiyuu Yakuhin Kogyo Kk 口腔内粘膜貼付剤
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
GB8521350D0 (en) 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
EP0236477B1 (en) 1985-09-06 1993-01-20 Baker Norton Pharmaceuticals, Inc. Use of 6-methylene-6-desoxy-n-cyclopropylmethyl-14-hydroxydihydronormorphine
US4760069A (en) 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4722928A (en) 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
US4730048A (en) 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
DE3750145T2 (de) 1986-06-10 1994-11-03 Euro Celtique Sa Zusammensetzung mit kontrollierter Freisetzung von Dihydrocodein.
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US5356900A (en) 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
GB8628728D0 (en) 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US4873076A (en) 1988-04-29 1989-10-10 Baker Cummins Pharmaceuticals, Inc. Method of safely providing anesthesia or conscious sedation
GB8813064D0 (en) 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5096715A (en) 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5086058A (en) 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
JP3178541B2 (ja) 1991-05-29 2001-06-18 キヤノン株式会社 画像処理方法及び装置
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
AU651247B2 (en) 1991-09-06 1994-07-14 Mcneilab, Inc. Composition comprising a tramadol material and acetaminophen and its use
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5225440A (en) 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
GB9203689D0 (en) 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
GB9204354D0 (en) 1992-02-28 1992-04-08 Biokine Tech Ltd Compounds for medicinal use
EP0647137B1 (en) 1992-06-22 2008-08-13 The Regents Of The University Of California Glycine receptor antagonists and the use thereof
US5352680A (en) 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US20010006967A1 (en) 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5633259A (en) 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
JPH08504189A (ja) 1992-09-21 1996-05-07 キン、ボーイ 低／非たんでき性オピオイド鎮痛剤の確認及び使用方法
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5585348A (en) 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
NZ260883A (en) 1993-07-01 1997-06-24 Euro Celtique Sa Oral sustained-release medicaments containing morphine
CN1230154C (zh) * 1993-07-01 2005-12-07 欧洲凯尔特公司 缓释组合物及制备药用组合物的方法
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4325465B4 (de) * 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
GB9319568D0 (en) 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
HU218673B (hu) 1993-10-07 2000-10-28 Euroceltique S.A. Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
DK0654263T3 (da) 1993-11-23 2002-04-29 Euro Celtique Sa Fremgangsmåde til fremstilling af et præparat med langvarig frigivelse
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5376662A (en) 1993-12-08 1994-12-27 Ockert; David M. Method of attenuating nerve injury induced pain
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
GB9414699D0 (en) 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
EP0799051B1 (en) 1994-12-12 2005-07-27 Omeros Corporation Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5692500A (en) 1995-01-09 1997-12-02 Gaston-Johansson; Fannie Pain measurement and recording tool and method
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
KR100245395B1 (ko) 1995-06-09 2000-03-02 그린 마틴, 브라이언 쥐 테슬리 장기간의 국소 마취를 제공하는 제형 및 그 방법
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9517883D0 (en) 1995-09-01 1995-11-01 Euro Celtique Sa Improved pharmaceutical ion exchange resin composition
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
EP0874828A4 (en) 1995-12-06 1999-09-01 Lilly Co Eli PAIN TREATMENT COMPOSITIONS
EP0888111B1 (en) 1996-03-08 2003-05-21 Nycomed Danmark A/S Modified release multiple-units dosage composition
PT914097E (pt) 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
JPH11508608A (ja) * 1996-04-17 1999-07-27 ニューロクライン バイオサイエンシーズ，インコーポレイテッド インスリン様成長因子結合タンパク質のリガンドインヒビターおよびそれらの使用方法
AU3404997A (en) * 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
WO1998024412A2 (en) * 1996-12-05 1998-06-11 The Board Of Trustees Of The University Of Illinois Compounds useful against diseases of the colon and methods for orally administering same
DE29719704U1 (de) 1997-02-14 1998-01-22 Gödecke AG, 10587 Berlin Stabile Zubereitungen von Naloxonhydrochlorid
SK282549B6 (sk) 1997-02-14 2002-10-08 G�decke Aktiengesellschaft Spôsob stabilizácie naloxonhydrochloridu
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19710008A1 (de) 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
US5780479A (en) 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
AU3690297A (en) 1997-07-30 1999-02-22 Universite De Montreal Portable and programmable interactive visual analogue scale data-logger device
DE69823520T2 (de) 1997-09-04 2005-05-12 Novoneuron, Inc., Miami Noribogain zur behandlung von schmerzen und drogenabhängigkeit
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
ATE210983T1 (de) 1997-11-03 2002-01-15 Stada Arzneimittel Ag Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US5957459A (en) 1998-04-27 1999-09-28 Chae; Myung Joo Banking card game
EP0960619B1 (de) 1998-05-28 2004-03-10 Krewel Meuselbach GmbH Retardiertes Schmerzmittel enthaltend Tilidin
DE19857766A1 (de) 1998-05-28 1999-12-02 Krewel Meuselbach Gmbh Retardiertes Schmerzmittel enthaltend Tilidin
DE29818454U1 (de) 1998-10-15 1999-01-14 Euroceltique S.A., Luxemburg/Luxembourg Opioid-Analgetikum
SE9803760D0 (sv) 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
FR2787715B1 (fr) 1998-12-23 2002-05-10 Synthelabo Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables
DE19859636A1 (de) * 1998-12-23 2000-06-29 Hexal Ag Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff
DE19901085C2 (de) 1999-01-14 2003-12-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6765010B2 (en) 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US6419595B1 (en) 1999-07-09 2002-07-16 Bridgestone Sports Co., Ltd. Solid golf ball
US6451007B1 (en) 1999-07-29 2002-09-17 Dale E. Koop Thermal quenching of tissue
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
PT1225897E (pt) * 1999-11-01 2005-01-31 John Rhodes Composicao para o tratamento da obstipacao e do sindroma do intestino irritavel
IL149600A0 (en) 1999-11-29 2002-11-10 Adolor Corp Novel methods and compositions involving opioids and antagonists thereof
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
WO2001068080A2 (en) 2000-03-15 2001-09-20 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
EP1280529A2 (en) 2000-05-05 2003-02-05 Pain Therapeutics, Inc. Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
AU5945801A (en) 2000-05-05 2001-11-20 Pain Therapeutics Inc Opoid antagonist compositions and dosage forms
HK1055078A1 (zh) 2000-06-09 2003-12-24 The Regents Of The University Of California 使用纳布啡和鸦片拮抗剂治疗疼痛的方法
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
DE10131113A1 (de) 2001-06-28 2003-01-23 Siemens Linear Motor Systems G Rotations-Elektromotor
WO2003004009A1 (en) 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition
DE20220910U1 (de) 2001-08-06 2004-08-05 Euro-Celtique S.A. Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
ATE431738T1 (de) 2001-08-06 2009-06-15 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
BR0212020A (pt) 2001-08-06 2005-08-16 Euro Celtique Sa Formas de dosagem, métodos para impedir o abuso de uma forma de dosagem, métodos para impedir o desvio de uma forma de dosagem, métodos para o tratamento de dor e método de preparação de uma forma de dosagem
EP1427476B1 (en) 2001-09-06 2009-03-25 Hans Gregersen Apparatus for stimulating a bodily hollow system and for measuring reactions to stimuli of such system
US20040253310A1 (en) * 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP1429739A1 (en) * 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2003073937A1 (en) 2002-03-06 2003-09-12 Euro-Celtique S.A. Analog scale for measuring pain
KR20040098660A (ko) 2002-03-14 2004-11-20 유로-셀티크 소시에떼 아노뉨 날트렉손 하이드로클로라이드 조성물
DE10215067A1 (de) 2002-04-05 2003-10-16 Euro Celtique Sa Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst
DE10215131A1 (de) 2002-04-05 2003-10-16 Euro Celtique Sa Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
BRPI0309544B8 (pt) * 2002-04-05 2021-05-25 Euro Celtique Sa preparação farmacêutica oral estável ao armazenamento compreendendo oxicodona e naloxona
EP1364649A1 (en) 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
RU2222260C1 (ru) 2002-07-08 2004-01-27 Сибирский государственный медицинский университет Способ дифференцированной оценки степени функциональной активности тонкой кишки
WO2004026262A2 (en) 2002-09-23 2004-04-01 Verion, Inc. Abuse-resistant pharmaceutical compositions
JP2006516969A (ja) 2003-01-23 2006-07-13 アモレパシフィック コーポレーション 徐放性製剤及びその製造方法
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050053659A1 (en) 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
EP1771160A2 (en) 2005-01-28 2007-04-11 Euroceltique S.A. Alcohol resistant dosage forms
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20070092576A1 (en) 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20070185145A1 (en) 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
WO2007111945A2 (en) 2006-03-22 2007-10-04 Trustees Of Boston University Method for management of diarrhea
US7879870B2 (en) 2006-04-19 2011-02-01 Smith Jill P Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
DE202006018609U1 (de) 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP2042176A1 (en) 2007-09-26 2009-04-01 Euro-Celtique S.A. Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease
BRPI0910780A2 (pt) 2008-07-07 2016-08-09 Euro Celtique Sa uso de antagonistas de opióides para o tratamento da retenção urinária
RU2522212C2 (ru) 2009-03-10 2014-07-10 Еуро-Селтик С.А. Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон
NO330672B1 (no) 2009-11-12 2011-06-06 Proxdynamics As Rotormekanisme for helikoptere
BR112013003150B1 (pt) 2010-08-13 2022-01-18 Euro-Celtique S.A. Uso de hidroxipropil celulose para a fabricação de formulações estáveis em armazenagem

Patent Citations (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3133132A (en) * 1960-11-29 1964-05-12 Univ California High flow porous membranes for separating water from saline solutions
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546876A (en) * 1967-11-02 1970-12-15 Philips Corp Hot-gas engine
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3950508A (en) * 1972-05-10 1976-04-13 Laboratoires Servier Process for obtaining pharmaceutical sustained releases
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US4088864A (en) * 1974-11-18 1978-05-09 Alza Corporation Process for forming outlet passageways in pills using a laser
US3966040A (en) * 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4160020A (en) * 1975-11-24 1979-07-03 Alza Corporation Therapeutic device for osmotically dosing at controlled rate
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4582835A (en) * 1983-12-06 1986-04-15 Reckitt & Colman Products Limited Analgesic compositions
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4957681A (en) * 1988-04-15 1990-09-18 Basf Aktiengesellschaft Preparation of pharmaceutical mixtures
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5508042A (en) * 1991-11-27 1996-04-16 Euro-Celtigue, S.A. Controlled release oxycodone compositions
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5549912A (en) * 1991-11-27 1996-08-27 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US6294195B1 (en) * 1991-12-24 2001-09-25 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5356467A (en) * 1992-08-13 1994-10-18 Euroceltique S.A. Controlled release coatings derived from aqueous dispersions of zein
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5591452A (en) * 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US6103261A (en) * 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5958452A (en) * 1994-11-04 1999-09-28 Euro-Celtique, S.A. Extruded orally administrable opioid formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6743442B2 (en) * 1994-11-04 2004-06-01 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US6706281B2 (en) * 1994-11-04 2004-03-16 Euro-Celtique, S.A. Melt-extrusion multiparticulates
US6335033B2 (en) * 1994-11-04 2002-01-01 Euro-Celtique, S.A. Melt-extrusion multiparticulates
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US6419959B1 (en) * 1996-12-11 2002-07-16 Klinge Pharma Gmbh Galenic composition containing opioid antagonists
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
US6306438B1 (en) * 1997-07-02 2001-10-23 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
US6277384B1 (en) * 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6114326A (en) * 1998-03-27 2000-09-05 Pharmacia & Upjohn Company Use of cabergoline in the treatment of restless legs syndrome
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
US20050163856A1 (en) * 1999-07-29 2005-07-28 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US20010053777A1 (en) * 1999-08-19 2001-12-20 Brecht Hans Michael Drug treatment for restless leg syndrome
US6258042B1 (en) * 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
US20020010127A1 (en) * 2000-02-08 2002-01-24 Benjamin Oshlack Controlled-release compositions containing opioid agonist and antagonist
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6696088B2 (en) * 2000-02-08 2004-02-24 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
US20020031552A1 (en) * 2000-06-30 2002-03-14 Mcteigue Daniel Teste masked pharmaceutical particles
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US6602868B2 (en) * 2000-10-31 2003-08-05 Pharmacia & Upjohn Company Treatments for restless legs syndrome
US6596900B2 (en) * 2001-04-19 2003-07-22 Pfizer Inc Fused bicyclic or tricyclic amino acids
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030069263A1 (en) * 2001-07-18 2003-04-10 Breder Christopher D. Pharmaceutical combinations of oxycodone and naloxone
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20050063909A1 (en) * 2001-08-06 2005-03-24 Euro-Celtique, S.A. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030092759A1 (en) * 2001-09-24 2003-05-15 Abuzzahab Faruk S. Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US20040052731A1 (en) * 2002-07-05 2004-03-18 Collegium Pharmaceuticals, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20050272776A1 (en) * 2004-06-04 2005-12-08 Adolor Corporation Compositions containing opioid antagonist
US20070185146A1 (en) * 2004-06-08 2007-08-09 Euro-Celtique S.A. Opioids for the treatment of the chronic obstructive pulmonary disease (copd)
US20080145429A1 (en) * 2005-02-28 2008-06-19 Petra Leyendecker Dosage Form Containing Oxycodone and Naloxone

Cited By (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8936808B1 (en) 1997-12-22 2015-01-20 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US9474750B2 (en) 1997-12-22 2016-10-25 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US9205082B2 (en) 1997-12-22 2015-12-08 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8673355B2 (en) 1997-12-22 2014-03-18 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8822487B2 (en) 1997-12-22 2014-09-02 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US8932630B1 (en) 1997-12-22 2015-01-13 Purdue Pharma L.P Opioid agonist/antagonist combinations
US8975273B2 (en) 1999-10-29 2015-03-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9669022B2 (en) 1999-10-29 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8980291B2 (en) 1999-10-29 2015-03-17 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9675611B1 (en) 1999-10-29 2017-06-13 Purdue Pharma L.P. Methods of providing analgesia
US9278074B2 (en) 1999-10-29 2016-03-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10076516B2 (en) 1999-10-29 2018-09-18 Purdue Pharma L.P. Methods of manufacturing oral dosage forms
US9056107B1 (en) 1999-10-29 2015-06-16 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9320717B2 (en) 1999-10-29 2016-04-26 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9669024B2 (en) 1999-10-29 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7842311B2 (en) 2000-02-08 2010-11-30 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US10350173B2 (en) 2000-02-08 2019-07-16 Purdue Pharma L.P. Tamper resistant oral opioid agonist formulations
US9801828B2 (en) 2000-02-08 2017-10-31 Purdue Pharma L.P. Tamper resistant oral opioid agonist formulations
US7842309B2 (en) 2000-02-08 2010-11-30 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7658939B2 (en) 2000-02-08 2010-02-09 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7718192B2 (en) 2000-02-08 2010-05-18 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8586088B2 (en) 2000-02-08 2013-11-19 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8936812B2 (en) 2000-02-08 2015-01-20 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7682632B2 (en) 2000-02-08 2010-03-23 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US10588865B2 (en) 2000-02-08 2020-03-17 Purdue Pharma L.P. Tamper resistant oral opioid agonist formulations
US9456989B2 (en) 2000-02-08 2016-10-04 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9278073B2 (en) 2000-02-08 2016-03-08 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8236351B2 (en) 2000-02-08 2012-08-07 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8357399B2 (en) 2000-02-08 2013-01-22 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9198863B2 (en) 2000-10-30 2015-12-01 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9572805B2 (en) 2000-10-30 2017-02-21 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9056052B1 (en) 2000-10-30 2015-06-16 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10022368B2 (en) 2000-10-30 2018-07-17 Purdue Pharma L.P. Methods of manufacturing oral formulations
US9682077B2 (en) 2000-10-30 2017-06-20 Purdue Pharma L.P. Methods of providing analgesia
US9669023B2 (en) 2000-10-30 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8951555B1 (en) 2000-10-30 2015-02-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9205055B2 (en) 2000-10-30 2015-12-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9205056B2 (en) 2000-10-30 2015-12-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9504681B2 (en) 2000-10-30 2016-11-29 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9289391B2 (en) 2000-10-30 2016-03-22 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9517236B2 (en) 2000-10-30 2016-12-13 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9023401B1 (en) 2000-10-30 2015-05-05 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9572804B2 (en) 2000-10-30 2017-02-21 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9526724B2 (en) 2000-10-30 2016-12-27 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9060940B2 (en) 2000-10-30 2015-06-23 Purdue Pharma L.P. Controlled release hydrocodone
US9084729B2 (en) 2001-05-11 2015-07-21 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9161937B2 (en) 2001-05-11 2015-10-20 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9168252B2 (en) 2001-05-11 2015-10-27 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9511066B2 (en) 2001-05-11 2016-12-06 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9480685B2 (en) 2001-05-11 2016-11-01 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9358230B1 (en) 2001-05-11 2016-06-07 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9283216B2 (en) 2001-05-11 2016-03-15 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9056051B2 (en) 2001-05-11 2015-06-16 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9283221B2 (en) 2001-05-11 2016-03-15 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9345701B1 (en) 2001-05-11 2016-05-24 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US7943173B2 (en) 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
US8815287B2 (en) 2001-08-06 2014-08-26 Purdue Pharma L.P. Opiod agonist formulations with releasable and sequestered antagonist
US8231901B2 (en) 2001-08-06 2012-07-31 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US8518443B2 (en) 2001-08-06 2013-08-27 Purdue Pharma, L.P. Opioid agonist formulations with releasable and sequestered antagonist
US7914818B2 (en) 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US9949930B2 (en) 2001-08-06 2018-04-24 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US10420762B2 (en) 2002-04-05 2019-09-24 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US9907793B2 (en) 2002-04-05 2018-03-06 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US8846090B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US20050245556A1 (en) * 2002-04-05 2005-11-03 Bianca Brogmann Pharmaceutical preparation containing oxycodone and naloxone
US8846091B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US9555000B2 (en) 2002-04-05 2017-01-31 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US9655855B2 (en) 2002-04-05 2017-05-23 Purdue Pharma L.P. Matrix for sustained, invariant and independent release of active compounds
US9149436B2 (en) 2003-04-21 2015-10-06 Purdue Pharma L.P. Pharmaceutical product comprising a sequestered agent
US10092519B2 (en) 2003-04-21 2018-10-09 Purdue Pharma L.P. Pharmaceutical products
US8399015B2 (en) 2003-08-28 2013-03-19 Abbvie Inc. Solid pharmaceutical dosage form
US8268349B2 (en) 2003-08-28 2012-09-18 Abbott Laboratories Solid pharmaceutical dosage form
US8309613B2 (en) 2003-08-28 2012-11-13 Abbvie Inc. Solid pharmaceutical dosage form
US8333990B2 (en) 2003-08-28 2012-12-18 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8691878B2 (en) 2003-08-28 2014-04-08 Abbvie Inc. Solid pharmaceutical dosage form
US20060194826A1 (en) * 2003-09-25 2006-08-31 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
US20070185147A1 (en) * 2004-06-08 2007-08-09 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
US8518925B2 (en) 2004-06-08 2013-08-27 Euro-Celtique S.A. Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US20070259045A1 (en) * 2005-01-28 2007-11-08 Euro-Celtique S.A. Alcohol Resistant Dosage Forms
US20080145429A1 (en) * 2005-02-28 2008-06-19 Petra Leyendecker Dosage Form Containing Oxycodone and Naloxone
US20110172259A1 (en) * 2005-02-28 2011-07-14 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20090169626A1 (en) * 2006-01-27 2009-07-02 Euro-Celtique S.A. Tamper resistant dosage forms
US8987290B2 (en) 2006-08-29 2015-03-24 Purdue Pharma L.P. Use of opioid formulations in needle-less drug delivery devices
US20100056554A1 (en) * 2006-08-29 2010-03-04 Jo Woodward Use of opioid formulations in needle-less drug delivery devices
US9763931B2 (en) 2006-08-30 2017-09-19 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9861628B2 (en) 2006-08-30 2018-01-09 Rhodes Pharmaceuticals L.P. Buprenorphine-wafer for drug substitution therapy
US9101625B2 (en) 2006-08-30 2015-08-11 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9370512B2 (en) 2006-08-30 2016-06-21 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US9216176B2 (en) 2006-09-15 2015-12-22 Cima Labs Inc. Abuse resistant drug formulation
US9974751B2 (en) 2006-09-15 2018-05-22 Cima Labs Inc. Abuse resistant drug formulation
US9572803B2 (en) 2006-09-15 2017-02-21 Cima Labs Inc. Abuse resistant drug formulation
US20110150991A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US10729657B2 (en) 2007-08-13 2020-08-04 Ohemo Life Sciences Inc. Abuse resistant forms of extended release morphine, method of use and method of making
US10314788B2 (en) * 2007-08-13 2019-06-11 Inspirion Delivery Sciences Llc Pharmaceutical compositions configured to deter dosage form splitting
US20110150971A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US11291634B2 (en) 2007-08-13 2022-04-05 OHEMO Life Sciences, Inc. Abuse resistant forms of extended release oxymorphone, method of use and method of making
US20110150969A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110150990A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110159090A1 (en) * 2007-08-13 2011-06-30 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110002985A1 (en) * 2007-08-13 2011-01-06 Abuse Deterrent Pharmaceutical, Llc Abuse resistant drugs, method of use and method of making
US20110159089A1 (en) * 2007-08-13 2011-06-30 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110150970A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US10736851B2 (en) 2007-08-13 2020-08-11 Ohemo Life Sciences Inc. Abuse resistant forms of extended release morphine with oxycodone, method of use and method of making
US10736852B2 (en) 2007-08-13 2020-08-11 OHEMO Life Sciences, Inc. Abuse resistant oral opioid formulations
US10688051B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences Llc Abuse resistant forms of extended release oxycodone, method of use, and method of making
US10729656B2 (en) 2007-08-13 2020-08-04 Ohemo Life Sciences Inc. Abuse resistant forms of immediate release oxycodone, method of use and method of making
US10736850B2 (en) 2007-08-13 2020-08-11 Ohemo Life Sciences Inc. Abuse resistant oral opioid formulations
US20110184007A1 (en) * 2007-08-13 2011-07-28 Inspirion Delivery Technologies, Llc Pharmaceutical compositions configured to deter dosage form splitting
US10702480B2 (en) 2007-08-13 2020-07-07 OHEMO Life Sciences, Inc. Abuse resistant forms of extended release morphine, method of use and method of making
US10695298B2 (en) 2007-08-13 2020-06-30 Inspirion Delivery Sciences, Llc Abuse resistant forms of extended release hydromorphone, method of use and method of making
US11285112B2 (en) 2007-08-13 2022-03-29 Oheno Life Sciences, Inc Abuse resistant forms of immediate release oxymorphone, method of use and method of making
US10688055B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences, Llc Abuse resistant forms of extended release morphine, method of use and method of making
US11045422B2 (en) 2007-08-13 2021-06-29 Oheno Life Sciences, Inc. Abuse resistant drugs, method of use and method of making
US10688052B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences Llc Abuse resistant forms of extended release oxymorphone, method of use and method of making
US10688053B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences, Llc Abuse resistant forms of extended release hydrocodone, method of use and method of making
US11191730B2 (en) 2007-08-13 2021-12-07 Ohemo Life Sciences Inc. Abuse resistant forms of immediate release hydromorphone, method of use and method of making
US10688054B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences Llc Abuse resistant forms of extended release morphine, method of use and method of making
US11278500B2 (en) 2007-08-13 2022-03-22 OHEMO Life Sciences, Inc. Abuse resistant forms of extended release hydrocodone, method of use and method of making
US20090142398A1 (en) * 2007-11-21 2009-06-04 Pharmascience Inc. Novel pharmaceutical compositions comprising a disintegration matrix
US20100047340A1 (en) * 2008-08-20 2010-02-25 Board Of Regents, The University Of Texas System Hot-melt extrusion of modified release multi-particulates
US9827202B2 (en) 2008-08-20 2017-11-28 Board Of Regents, The University Of Texas System Hot-melt extrusion of modified release multi-particulates
RU2483713C2 (ru) * 2008-08-20 2013-06-10 Борд Оф Риджентс, Зе Юниверсити Оф Техас Систем Экструзия горячего расплава множественных частиц модифицированного высвобождения
US9192578B2 (en) 2008-08-20 2015-11-24 Board Of Regents, The University Of Texas System Hot-melt extrusion of modified release multi-particulates
US9642801B2 (en) 2008-10-30 2017-05-09 Gruenenthal Gmbh And potent tapentadol dosage forms
US8362029B2 (en) 2008-12-31 2013-01-29 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
US8987291B2 (en) 2008-12-31 2015-03-24 Upsher Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9820983B2 (en) 2009-03-10 2017-11-21 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9814679B2 (en) 2009-06-05 2017-11-14 Euro-Celtique S.A. Tamper resistant dosage form comprising a matrix and melt-extruded particulates comprising a drug
WO2010140007A3 (en) * 2009-06-05 2011-11-17 Euro-Celtique S.A. Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug
US9456985B2 (en) 2009-09-17 2016-10-04 Upsher-Smith Laboratories, Inc. Sustained-released product comprising a combination of a non-opioid amine and a non-steroidal, anti-inflammatory drug
US9023390B2 (en) 2009-09-17 2015-05-05 Upsher-Smith Laboratories, Inc. Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
US9700508B2 (en) 2010-05-10 2017-07-11 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
US11207317B2 (en) 2012-08-22 2021-12-28 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
US11571390B2 (en) 2013-03-15 2023-02-07 Othemo Life Sciences, Inc. Abuse deterrent compositions and methods of use
US10420726B2 (en) 2013-03-15 2019-09-24 Inspirion Delivery Sciences, Llc Abuse deterrent compositions and methods of use
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10639281B2 (en) 2013-08-12 2020-05-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10568881B2 (en) 2013-10-31 2020-02-25 Clexio Biosciences Ltd. Immediate release abuse-deterrent granulated dosage forms
US11844796B2 (en) 2013-10-31 2023-12-19 Clexio Biosciences Ltd. Immediate release abuse-deterrent granulated dosage forms
US9757371B2 (en) 2013-10-31 2017-09-12 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US11207318B2 (en) 2013-10-31 2021-12-28 Clexio Biosciences Ltd. Immediate release abuse-deterrent granulated dosage forms
US9707224B2 (en) 2013-10-31 2017-07-18 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US10258616B2 (en) 2013-11-13 2019-04-16 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US10792254B2 (en) 2013-12-17 2020-10-06 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9289425B2 (en) 2013-12-20 2016-03-22 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10478429B2 (en) 2015-10-07 2019-11-19 Patheon Softgels, Inc. Abuse deterrent dosage forms
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11992468B2 (en) 2019-05-07 2024-05-28 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Also Published As

Publication number Publication date
US20180214443A1 (en) 2018-08-02
AP2004003137A0 (en) 2004-09-30
CY1108914T1 (el) 2014-07-02
ZA200407267B (en) 2005-08-31
EP1492505A2 (en) 2005-01-05
CY1118921T1 (el) 2018-01-10
US20170112828A1 (en) 2017-04-27
GEP20074022B (en) 2007-01-10
US20140045877A1 (en) 2014-02-13
CA2478523A1 (en) 2003-10-16
EP2425825A1 (en) 2012-03-07
DK2425825T3 (en) 2017-02-20
AP2043A (en) 2009-09-09
EP3241548A1 (en) 2017-11-08
EP2311438A1 (en) 2011-04-20
CA2708900C (en) 2019-06-04
KR20040098050A (ko) 2004-11-18
JP2010180233A (ja) 2010-08-19
WO2003084520A2 (en) 2003-10-16
IL163990A0 (en) 2005-12-18
HK1246176A1 (en) 2018-09-07
ATE418967T2 (de) 2009-01-15
EP2308475A1 (en) 2011-04-13
RU2297225C2 (ru) 2007-04-20
SI1492505T1 (sl) 2015-10-30
RU2295344C2 (ru) 2007-03-20
KR20070006945A (ko) 2007-01-11
RU2006128796A (ru) 2008-02-20
KR100784341B1 (ko) 2007-12-13
ZA200407317B (en) 2005-08-31
TWI345973B (en) 2011-08-01
ES2733051T1 (es) 2019-11-27
EP2425824B1 (en) 2017-05-10
PT2425821T (pt) 2017-08-23
EP2308474A1 (en) 2011-04-13
DK1492505T3 (en) 2015-08-10
TNSN04192A1 (fr) 2007-03-12
JP2005528375A (ja) 2005-09-22
EP2316429A1 (en) 2011-05-04
EP2425825B9 (en) 2017-03-01
DE17169621T1 (de) 2019-12-19
JP2014129397A (ja) 2014-07-10
TW200403996A (en) 2004-03-16
CO5611100A2 (es) 2006-02-28
JP5107954B2 (ja) 2012-12-26
SI2425824T1 (sl) 2017-06-30
CN1646102A (zh) 2005-07-27
TW200408394A (en) 2004-06-01
IL182742A0 (enrdf_load_stackoverflow) 2007-07-24
EP2243471A1 (en) 2010-10-27
KR100717591B1 (ko) 2007-05-15
RU2004131870A (ru) 2005-05-27
EP1492506B2 (en) 2016-06-29
ES2733044T1 (es) 2019-11-27
ES2627300T3 (es) 2017-07-27
TWI334779B (en) 2010-12-21
HUE031668T2 (en) 2017-07-28
US9655855B2 (en) 2017-05-23
CY1116640T1 (el) 2017-03-15
AR090677A2 (es) 2014-11-26
JP4620355B2 (ja) 2011-01-26
JP2005529097A (ja) 2005-09-29
AU2003224041A1 (en) 2003-10-20
SI1492506T1 (sl) 2009-04-30
MXPA04009714A (es) 2005-12-05
US9555000B2 (en) 2017-01-31
US20050245556A1 (en) 2005-11-03
FIU20070322U0 (fi) 2007-08-17
WO2003084504A3 (en) 2004-03-11
JP5932209B2 (ja) 2016-06-08
EP2425824A1 (en) 2012-03-07
US9907793B2 (en) 2018-03-06
ES2546010T3 (es) 2015-09-17
EP3326618A1 (en) 2018-05-30
AU2003224040A1 (en) 2003-10-20
KR20040098052A (ko) 2004-11-18
ES2320748T5 (es) 2017-02-20
US8846090B2 (en) 2014-09-30
HK1072366A1 (en) 2005-08-26
TWI337077B (en) 2011-02-11
MA27116A1 (fr) 2004-12-20
RU2004130845A (ru) 2005-06-10
DK200700243U3 (da) 2008-01-25
EP2425823A1 (en) 2012-03-07
BR0309004A (pt) 2005-02-01
US20140045878A1 (en) 2014-02-13
ES2608006T3 (es) 2017-04-05
IL200621A (en) 2016-02-29
CA2478515C (en) 2010-09-28
PH12018000176A1 (en) 2018-11-19
PT2425825T (pt) 2017-02-13
AU2003224041B2 (en) 2006-07-13
IL200621A0 (en) 2011-07-31
CA2478515A1 (en) 2003-10-16
CA2708900A1 (en) 2003-10-16
HK1072367A1 (en) 2005-08-26
LT2425825T (lt) 2017-02-27
MXPA04009713A (es) 2005-01-11
EP1639996A1 (en) 2006-03-29
EP1492505B1 (en) 2015-06-03
AP2397A (en) 2012-04-23
ES2320748T3 (es) 2009-05-28
EP2319496A1 (en) 2011-05-11
EP2425825B1 (en) 2016-11-16
US8846091B2 (en) 2014-09-30
US20140296277A1 (en) 2014-10-02
WO2003084504A2 (en) 2003-10-16
LT2425821T (lt) 2017-07-25
HUE032529T2 (en) 2017-09-28
HK1166463A1 (en) 2012-11-02
RU2342935C2 (ru) 2009-01-10
DK1492506T4 (en) 2016-10-03
PT2425824T (pt) 2017-08-23
US20150005335A1 (en) 2015-01-01
AP2004003138A0 (en) 2004-09-30
JP2009167198A (ja) 2009-07-30
DK200700243U1 (da) 2007-11-09
US20120183612A1 (en) 2012-07-19
DE20308437U1 (de) 2003-11-13
DE60325567D1 (de) 2009-02-12
CY1119120T1 (el) 2018-02-14
JP4755810B2 (ja) 2011-08-24
EP1639997A1 (en) 2006-03-29
FI7846U1 (fi) 2008-04-28
CN100411611C (zh) 2008-08-20
CN102813654A (zh) 2012-12-12
HK1254279A1 (en) 2019-07-19
SI2425821T1 (sl) 2017-06-30
CN1642529A (zh) 2005-07-20
EP2425821B1 (en) 2017-05-10
DK2425824T3 (en) 2017-08-28
HUE032656T2 (en) 2017-10-30
PT1492505E (pt) 2015-10-06
NZ535286A (en) 2007-07-27
DE20321531U1 (de) 2007-11-22
PT1492506E (pt) 2009-03-16
CN107669681A (zh) 2018-02-09
DK2425821T3 (en) 2017-08-28
DK1492506T3 (da) 2009-03-16
DK2425821T5 (en) 2018-02-12
DE20308436U1 (de) 2003-09-18
EP1492506A2 (en) 2005-01-05
SI2425825T1 (sl) 2017-05-31
US20170231978A1 (en) 2017-08-17
GEP20084485B (en) 2008-09-25
AU2003224040B2 (en) 2006-06-22
CY1119168T1 (el) 2018-02-14
CO5611093A2 (es) 2006-02-28
US20120108621A1 (en) 2012-05-03
DE17154462T1 (de) 2019-12-19
IL163989A0 (en) 2005-12-18
AR039379A1 (es) 2005-02-16
EP2425821A1 (en) 2012-03-07
IL163990A (en) 2010-04-29
TW200716113A (en) 2007-05-01
CN1646102B (zh) 2012-08-15
GEP20064022B (en) 2007-01-10
BRPI0309544B1 (pt) 2018-04-03
LT2425824T (lt) 2017-07-25
BR0309544A (pt) 2005-02-01
AR039378A1 (es) 2005-02-16
HUE027004T2 (en) 2016-08-29
BRPI0309544B8 (pt) 2021-05-25
EP1492506B1 (en) 2008-12-31
ES2627298T3 (es) 2017-07-27
EP2316428A1 (en) 2011-05-04
MA27249A1 (fr) 2005-03-01
WO2003084520A3 (en) 2004-03-11
DK2425824T5 (en) 2018-02-12
US10420762B2 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
US9655855B2 (en) Matrix for sustained, invariant and independent release of active compounds
HK1156538A (en) Matrix for sustained, invariant and independent release of active compounds
HK1158055A (en) Matrix for sustained, invariant and independent release of active compounds
HK1156525A (en) Matrix for sustained, invariant and independent release of active compounds
HK1156539A (en) Matrix for sustained, invariant and independent release of active compounds
HK1156537A (en) Matrix for sustained, invariant and independent release of active compounds
HK1072366B (en) Matrix for sustained, invariant and independent release of active compounds
HK1092360A (en) Matrix for sustained, invariant and independant release of active compounds
HK1092362A (en) Matrix for sustained, invariant and independant release of active compounds
AU2006203172A1 (en) Matrix for sustained, invariant and independent release of active compounds

Legal Events

Date Code Title Description
AS Assignment

Owner name: EURO-CELTIQUE, S.A., LUXEMBOURG

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BROGMAN, BRIANCA;MUHLAU, SILKE;SPITZLEY, CHRISTOF;REEL/FRAME:016648/0667;SIGNING DATES FROM 20041112 TO 20041126

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: PURDUE PHARMA L.P., CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EURO-CELTIQUE S.A.;REEL/FRAME:033852/0408

Effective date: 20140926